Narendranath Epperla
( out of 41 reviews )

Narendranath Epperla, MD, MS, FACP

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
2000 Circle of Hope
Salt Lake City , UT 84112
801-585-2626
Get Directions

Dr. Narendranath Epperla is an Associate Professor in the Division of Hematology and Hematologic Malignancies in the Department of Medicine at the Huntsman Cancer Institute, University of Utah. He serves as the Associate Chief of Clinical Research and Director of the Phase I Clinical Trials Program for Hematologic Malignancies. His clinical expertise focuses on the management of lymphoid malignancies, including non-Hodgkin lymphoma, Hodgkin lymphoma, primary and secondary CNS lymphomas, and Waldenström macroglobulinemia.

Dr. Epperla is highly active in translational and clinical research, with a particular emphasis on early-phase clinical trials evaluating novel therapeutic combinations for lymphoid malignancies, as well as the identification of blood-based biomarkers predictive of treatment response. He serves as the national principal investigator for multiple investigator-initiated and consortium-based studies and is an active member of the Alliance Lymphoma Committee and the National Clinical Trials Network. He is also a Multi-Principal Investigator within the Experimental Therapeutics Clinical Trials Network.

Dr. Epperla is a member of several professional societies, including the American Society of Hematology, American Society of Clinical Oncology, American Society for Transplantation and Cellular Therapy, and the American Association for Cancer Research. He has authored more than 200 peer-reviewed publications and serves on the editorial boards of several high-impact journals, including Journal of Hematology and Oncology, BMC Medicine, and Frontiers in Immunology.

To schedule an appointment: New Patients: 801-585-6906 Returning Patients: 801-585-2626 or schedule through MyChart.

For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

Specialties

  • Waldenstrom Macroglobulinemia
  • Hodgkin Lymphoma
  • Central Nervous System Lymphoma
  • Indolent Non-Hodgkin Lymphoma
  • Aggressive Non-Hodgkin Lymphoma
  • Hematology
  • Hairy Cell Leukemia

Patient Rating

Patients consistently praise Dr. Epperla's expertise and clear explanations, noting he thoroughly reviews imaging and biopsy results and makes diagnoses and treatment plans understandable. Many mention his compassion, patience, and attention to both physical and emotional well-being, and they appreciate the support from his staff and team. Reviewers report he initiates treatment promptly and can be appropriately aggressive when needed; one patient credited participation in his clinical trial with saving their life. Feedback is overwhelmingly positive, though a few patients noted long clinic wait times.

Generated via Patient Reviews

4.9 /5
( out of 41 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.

2026-04-22
HUNTSMAN CANCER CENTER

I am forever grateful that when we found out that I had stage 4 cancer that I was at the Huntsman Center so that I could have Dr Epperla as my doctor and to be part of his clinical trial. It truly saved my life. I will never be able to fully express my gratitude.

2026-04-16
HUNTSMAN CANCER CENTER

Dr. Eppera makes one feel comfortable and assured of treatment. He's great.

2026-03-07
HUNTSMAN CANCER CENTER

Excellent care

2026-02-14
HUNTSMAN CANCER CENTER

It is obvious that Dr Epperla cares about you and the care you receive. I appreciate the time he spent reviewing my heath status and answering my questions. I appreciate his insight he has offered for future care.

2026-01-28
HUNTSMAN CANCER CENTER

Dr Epperla is so knowledgeable about his specialty and is passionate about caring for his patients and making sure we get the very best care. We are so grateful to be under his care.

2026-01-14
HUNTSMAN CANCER CENTER

Dr. Epperla is incredible. He's super knowledgeable and explains things in a way that I understand. He's not just focused on the physical symptoms, but wants to know how I'm coping with having cancer. Thank you Dr. Epperla for your patience & your compassion for those of us who are navigating cancer. 10/10 recommend Dr. Epperla.

2026-01-08
HUNTSMAN CANCER CENTER

Wonderful treatment

2025-12-17
HUNTSMAN CANCER CENTER

Dr. Epperla is very good at what he does. My mother has improved a lot since he diagnosed her with lymphoma. He makes himself easy to understand, and when I ask him something, he doesn't leave me with any doubts. He's very kind and always smiling, which I really appreciate. His team is also very nice, including his assistant Sara and his nurse. Thank you for helping my mother with her illness. [TRANSLATED]

2025-11-20
HUNTSMAN CANCER CENTER

Dr Epperla was very kind and knowledgeable.

2025-10-09
HUNTSMAN CANCER CENTER

Dr. Epperla explained every step that needed to be taken in my treatment and also answered every question my wife had. He was very aggressive in the treatment plan and hit the ground running at full speed and did not stop. He and his staff have been the best blessing we could have asked for.

2025-09-18
HUNTSMAN CANCER CENTER

Dr. Epperla has been an amazing physician offering care and compassion, while providing exceptional education regarding my care.

2025-08-30
HUNTSMAN CANCER CENTER

Dr. Epperla was personable and knowledgeable, and took the time to explain information in understandable terminology. I am happy we chose Huntsman for my care!

2025-06-12
HUNTSMAN CANCER CENTER

Very nice easy to talk to talked to me in layman's terms so I could understand

2025-06-06
HUNTSMAN CANCER CENTER

Dr. Epperla is very Dr Epperla has a great way of explaining disease in a way that is easy to understand and makes a person feel confident of his skills.

2025-05-09
HUNTSMAN CANCER CENTER

Waited from 11.20 am until about 2pm. Delays happen but need to be planned for in the scheduled number of appointments. Was much too long and needed protein to eat

2025-05-01
HUNTSMAN CANCER CENTER

Very good information on my care

2025-02-28
HUNTSMAN CANCER CENTER

He is very competant.

2025-02-12
HUNTSMAN CANCER CENTER

Dr. Epperla is a stud! He has been everything you would ask from your physician; very professional knowledgeable, kind, and extremely concerned about my on going mental and physical state during treatment. He takes the time to break down technical aspects of my treatment into understandable terms and walks me through what to expect. I will be forever indebted to him for his support and care.

2025-02-12
HUNTSMAN CANCER CENTER

He took the time needed to explain test results and plan of action for my health care. He is a very thoughtful doctor.

2025-01-16
HUNTSMAN CANCER CENTER

He is an amazing doctor. He explains everything and old-fashioned words and drawings.

2024-12-19
HUNTSMAN CANCER CENTER

Very nice experience

2024-11-14
HUNTSMAN CANCER CENTER

He's caring and very knowledgable. I feel I am getting the best of care with Dr. Epperla and his team.

2024-11-07
HUNTSMAN CANCER CENTER

Knows his stuff! Did a great job in explaining what my lymphoma is and how to best treat it

2024-10-10
HUNTSMAN CANCER CENTER

Dr. Epperla was absolutely amazing. Our family was so impressed by his knowledge, kindness and willingness to begin this treatment process as soon as possible. We were able to see him from out-of-state in a very timely fashion and he had very thoroughly reviewed MRI and biopsy results before our visit. He explained in-depth the diagnosis and had a good plan in place. We are so very thsnful for everything he has done so far and have extreme confidence in him s as me his team going forward. Thank-you for all you do.

2024-09-17
HUNTSMAN CANCER CENTER

He is a wonderful doctor. He explains things and is honest. We appreciate his knowledge and would recommend him to others.

2024-09-12
HUNTSMAN CANCER CENTER

I was very impressed with him.

Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

Dr. Narendranath Epperla is an Associate Professor in the Division of Hematology and Hematologic Malignancies in the Department of Medicine at the Huntsman Cancer Institute, University of Utah. He serves as the Associate Chief of Clinical Research and Director of the Phase I Clinical Trials Program for Hematologic Malignancies. His clinical expertise focuses on the management of lymphoid malignancies, including non-Hodgkin lymphoma, Hodgkin lymphoma, primary and secondary CNS lymphomas, and Waldenström macroglobulinemia.

Dr. Epperla is highly active in translational and clinical research, with a particular emphasis on early-phase clinical trials evaluating novel therapeutic combinations for lymphoid malignancies, as well as the identification of blood-based biomarkers predictive of treatment response. He serves as the national principal investigator for multiple investigator-initiated and consortium-based studies and is an active member of the Alliance Lymphoma Committee and the National Clinical Trials Network. He is also a Multi-Principal Investigator within the Experimental Therapeutics Clinical Trials Network.

Dr. Epperla is a member of several professional societies, including the American Society of Hematology, American Society of Clinical Oncology, American Society for Transplantation and Cellular Therapy, and the American Association for Cancer Research. He has authored more than 200 peer-reviewed publications and serves on the editorial boards of several high-impact journals, including Journal of Hematology and Oncology, BMC Medicine, and Frontiers in Immunology.

To schedule an appointment: New Patients: 801-585-6906 Returning Patients: 801-585-2626 or schedule through MyChart.

For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

Board Certification and Academic Information

Academic Departments Internal Medicine -Associate Professor
Academic Divisions Hematology & Hematologic Malignancies

Education history

Professional Medical Medicine, Surgery - Kamineni Institute of Medical Sciences M.B.B.S.
Internship Internal Medicine - Marshfield Clinic/Ministry Saint Joseph¿s Hospital Intern
Residency Internal Medicine - Marshfield Clinic/Ministry Saint Joseph¿s Hospital Resident
Chief Resident Internal Medicine - Marshfield Clinic/Ministry Saint Joseph¿s Hospital Chief Resident
Fellowship Hematology/Oncology - Medical College of Wisconsin Fellow
Graduate Training Clinical and Translational Science Institute of Southeast Wisconsin, Medical College of Wisconsin M.S.

Selected Publications

Journal Article

  1. Wang JS, Ellsworth BL, Melody M, Epperla N, Stephens DM, Romancik JT, Cortese MJ, Bhansali RS, Moyo TK, Kenkre VP, Ollila TA, Hess BT, Fitzgerald LA, Shouse G, Matasar MJ, Herr MM, Davis JA, Jesme C, Pelcovits A, Moreira J, Lin AY, Ma S, Winter JN, Danilov AV, Shah NN, Barta SK, Cohen JB, Gordon LI, Grover NS, Karmali (2026). Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC Consortium. Blood advances, 10(3), 725-732.
  2. Melody M, Grover NS, Franco S, Romancik JT, Cortese MJ, Moyo TK, Bhansali RS, Ollila TA, Kenkre VP, Fitzgerald LA, Hess BT, Matasar MJ, Shouse G, Annunzio K, Herr MM, Davis JA, Jesme C, Pelcovits A, Moreira J, Ma S, Winter JN, Lin AY, Danilov AV, Roy I, Barta SK, Gordon LI, Stephens DM, Cohen JB, Epperla N, Karmali (2026). Outcomes of Bispecific Antibodies After CAR T-Cell Failure for Large B-cell Lymphoma- Results from the ABC Consortium. Blood advances, 10(1), 228-232.
  3. Cliff ERS, Pelaez GD, Wan F, Iyengar V, Zhou J, Chung K, Abdel-Razeq N, Allen J, Major A, Sharp J, Epperla N, Gould P, Cherng HJ, Houshyar S, Wallace DS, Lynch RC, Kallam A, Mei MG, Merryman RW, Fleyshman M, Rhodes JM, Kidwell A, Fenske TS, Malakhov N, Mulvey E, Watkins MP, Alhaj Moustafa M, Hilal T, Nowakowski GS, Wang Y, Torka P, Russler-Germain D (2026). Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma. Clinical cancer research, 32(1), 159-168.
  4. Alderuccio JP, Baggio D, Han S, Ghione P, Nizamuddin IA, Khwaja J, Saha A, Dong N, Wang Y, Cherng HJ, Tolu SS, Wagner-Johnston ND, Ollila TA, Grover NS, Koff JL, Desai A, Ramakrishnan Geethakumari P, Moyo TK, Sandoval-Sus J, Epperla N, Wallace DS, Kamdar M, Tavarozzi R, Danilov AV, Tun HW, Munoz J, Narkhede MS, Rhodes JM, Prica A, Kuhnl A, Maraj AM, Okosun J, Smith J, Osborne W, Calvert V, El-Sharkawi D, Hilali A, Collins GP, Linton K, Elmusharaf N, Santarsieri A, Karim F, Firas FB, Monick S, Trutzer IM, Can J, Ayers AA, Calabrese De Feo J, Sharp J, Ghosh N, Treitman R, Kallam A, Okcu I, Abeyakoon C, Hann W, Barrett A, Deshani V, Kahl BS, Chavez JC, Olszewski AJ, Cwynarski (2026). Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma. Blood,
  5. Vaughn JL, Taza G, Munir M, Rimmalapudi S, Epperla (2026). Trends in Incidence and Survival of Patients With Primary Effusion Lymphoma in the United States: A Population Based Cohort Study. Hematological oncology, 44(1), e70168.
  6. Sharp J, Strati P, Bhatta S, Huang JJ, Thomas CJ, Elghawy O, Reef D, Gorzewski AM, Wang JS, Shouse G, Reinert C, Teferra A, Toro Velez E, Pelcovits A, Ollila TA, Clark WB, Yazbeck V, Maakaron JE, Kamdar M, Fitzgerald LA, Danilov AV, Karmali R, Grover NS, Barta SK, Voorhees TJ, Chen AI, Shadman M, Ahmed S, Epperla (2026). Real-World Outcomes and Toxicities of CAR-T in Relapsed/Refractory Follicular Lymphoma: A Multicenter Cohort Study. Blood advances,
  7. Swomley A, Epperla N, Horns J, Das R, Hu B, Ermann (2026). CLO26-125: Treatment Intensity of Dose-Adjusted EPOCH-R and Its Relationship to Outcomes in Aggressive B-Cell Non-Hodgkin Lymphoma. Journal of the National Comprehensive Cancer Network, 24(3.5),
  8. Arnold ZJ, Lundberg J, Wiczer T, Handley D, Bond D, Sawalha Y, Sigmund A, Reneau J, Hanel W, Sharp J, Youssef Y, Alinari L, Brammer J, Christian B, Baiocchi R, Maddocks K, Epperla N, Voorhees T (2026). Clinical characteristics associated with terminal methotrexate clearance in patients with non-Hodgkin lymphomas receiving high-dose methotrexate. Journal of oncology pharmacy practice, 10781552261417588.
  9. Munir M, Sayed A, Ghazi S, Yang EH, Guha A, Epperla N, Addison (2026). Cardiotoxicity prevention trials in the era of contemporary cancer therapies: a systematic review. Cardio-oncology (London, England),
  10. Sharp J, Bhatta S, Takacs N, Tong K, Youssef Y, Bond DA, Sawalha Y, Sigmund A, Alinari L, Baiocchi R, Maddocks K, Christian B, Voorhees TJ, Epperla (2026). Impact of baseline osseous involvement on outcomes in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Blood neoplasia, 3(2), 100227.
  11. Vasu S, Denlinger N, Song NJ, Elsberry D, Zhao Q, Yu L, Bezerra E, Szuminski N, Schneider D, Dash P, Wirthlin L, Epperla N, Sawalha Y, Woyach J, Nishat S, Rogers K, Bhat S, Ghoneim H, Behbehani G, Voorhees T, Larkin K, Kittai A, Churchill V, George E, Lamb M, Lee D, Chan W, Krull A, Orentas R, O'Donnell L, Li Z, Alinari L, de Lima (2026). Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22. Research square,
  12. Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington SF, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith SD, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson PC, Grover NS, Merril M, Crombie JL, Shafagati N, Sterling C, Nastoupil LJ, Epperla N, Ayers E (2025). Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers. Haematologica, 110(3), 706-714.
  13. Samples L, Sadrzadeh H, Frigault MJ, Jacobson CA, Hamadani M, Gurumurthi A, Strati P, Shouval R, Noy A, Riedell PA, Dahiya S, Maloney DG, Till BG, Hirayama AV, Gauthier J, Gopal AK, Smith SD, Poh C, Lynch RC, Ujjani C, Di M, Raghunathan V, Shakib-Azar M, Naresh KN, Gooley TA, Yared JA, Jain MD, Locke FL, Leslie LA, Epperla N, Ghosh M, Skarbnik AP, Hill BT, Kamdar M, Ortiz-Maldonado V, Martínez-Cibrian N, Shune L, Shadman (2025). Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma. Blood, 145(23), 2762-2767.
  14. Voorhees TJ, McLaughlin EM, Torka P, Florindez J, Kim NH, Moyo TK, Reves H, Sumransub N, Deshpande S, Rose A, Duarte C, Faisal MS, Hamid S, Subbiah S, Ayyappan S, Shea L, Cortese M, Patel K, Major A, Saeed H, Svoboda J, Desai S, Geethakumari PR, Hamadani M, Grover N, Epperla (2025). Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers. Blood cancer journal, 15(1), 45.
  15. Karmali R, Shouse G, Torka P, Moyo TK, Romancik J, Barta SK, Bhansali R, Cohen JB, Shah NN, Zurko J, Kenkre VP, Hess B, Stephens DM, Fitzgerald L, Ollila T, Tabiti B, Roy I, Ma S, Winter J, Pro B, Moreira J, Danilov AV, David K, Gordon LI, Epperla (2025). Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy. Blood cancer journal, 15(1), 43.
  16. Borja-Montes OF, Bode A, Escobar-Gil T, Toro-Pedroza A, Epperla N, Andritsos L (2025). Gender Disparity in Enrollment in Clinical Trials for Hairy Cell Leukemia Treatments in the Last 40 Years. EJHaem, 6(3), e70065.
  17. Epperla N, Lucero M, Bailey T, Mirams L, Cheung J, Amet M, Milligan G, Chen (2025). How well does loncastuximab tesirine work after chimeric antigen receptor T-cell treatment in diffuse large B-cell lymphoma? A plain language summary of a real-world evidence study. Future oncology (London, England), 21(15), 1827-1836.
  18. Torka P, Grover NS, Voorhees TJ, Karmali R, Annunzio K, Watkins MP, Anampa-Guzmán A, Reves H, Tavakkoli M, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Shouse G, Olszewski AJ, Epperla (2025). Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study. Hematological oncology, 43(3), e70087.
  19. St-Pierre F, Bhatta S, Doukas PG, Jenkin M, Annunzio K, Rojek AE, Gibson A, Tiger YK, McCall B, Alhamad K, Hansen A, Alderuccio JP, Adewale O, Patel K, Trabolsi A, Lossos IS, Fitzgerald L, Ollila TA, Matasar MJ, Kline J, Karmali R, Epperla (2025). Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma-Results from a multicenter cohort study. Blood cancer journal, 15(1), 110.
  20. Sharp J, Shana'ah AY, Voorhees TJ, Bond DA, Sawalha Y, Sigmund A, Hanel W, Sehgal L, Alinari L, Baiocchi R, Maddocks K, Jones D, Christian B, Epperla (2025). Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma. Journal of the National Comprehensive Cancer Network, 23(7), 1-5.
  21. Sharp J, Zhao Q, Voorhees TJ, Bond DA, Sawalha Y, Reneau J, Sigmund A, Hanel W, Sehgal L, Alinari L, Baiocchi R, Brammer JE, Maddocks K, Christian B, Bezerra E, Denlinger N, Vasu S, De Lima M, Prosek J, Epperla (2025). Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphoma. British journal of haematology, 207(3), 992-1001.
  22. Cappelli L, Kayne A, Newman J, Elguindy A, Epperla N, Palmer JD, Outschoorn UM, Porcu P, Shi W, Alnahhas (2025). Primary central nervous system lymphoma: Predictors of response to induction therapy and patterns of progression. Neuro-oncology advances, 7(1), vdaf082.
  23. Bajwa A, Zhao Q, Geer M, Lin C, Westholder J, Maakaron J, Ghosh M, Frame D, Galal A, Tossey J, Ahmed N, Bezerra E, Denlinger N, de Lima M, Epperla N, Caimi P, Voorhees (2025). Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis. Blood advances, 9(1), 170-175.
  24. Kharfan-Dabaja MA, Mohty R, Easwar N, Johnston P, Iqbal M, Epperla N, Yared J, Ahmed N, Hamadani M, Beitinjaneh A, Narkhede M, Jagadeesh D, Ramakrishnan Geethakumari P, Dholaria B, Gergis U, Munoz J, Sandoval-Sus J, Locke FL, Fein J, Khurana A, Ayala E, Annunzio K, Rapoport AP, Lutfi F, Akhtar OS, Lekakis L, Mehta A, Oluwole OO, Logue J, Jain MD, Shore T, Durani U, Alhaj Moustafa M, McGuirk J, Lin Y, Yamshon S, Chavez J (2025). Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study. Bone marrow transplantation, 60(5), 632-639.
  25. LeHanka AM, Kebede AM, Amirmokhtari N, Stanek JR, Willen F, Yeager N, Christian B, Epperla N, Sawalha Y, Sigmund AM, Brammer JE, Voorhees TJ, Reneau JC, Baiocchi RA, Maddocks KJ, Cairo MS, Audino AN, Bond D (2025). Differences in Observed Outcomes and Toxicities for Adolescent and Young Adult Patients With Aggressive Mature B-Cell Lymphomas Treated at an Adult Versus Pediatric Cancer Center. Pediatric blood & cancer, 72(6), e31664.
  26. Epperla N, Olszewski AJ, Ayers EC, Ahmed (2025). Management of Adverse Reactions to Loncastuximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Hematological oncology, 43(5), e70128.
  27. Sharp J, Olszewski AJ, Epperla (2025). Identifying high-risk patients with MALT lymphoma undergoing first-line therapy for disease progression. Expert review of hematology, 18(12), 1027-1034.
  28. Thiruvengadam SK, Ahn KW, Patel J, Lian Q, Hertzberg M, Epperla N, Metheny L, Hong S, Jain T, Aljurf M, Beitinjaneh A, Vaughn J, Gopal A, Iqbal M, Wirk B, Manjappa S, Oliver C, Mohty R, Shadman M, Turtle C, Hamadani M, Herrera A (2025). CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis. American journal of hematology, 100(10), 1803-1812.
  29. Altomare NJ, Herr MM, Nair NM, Stephens DM, Cohen JB, Epperla N, Cortese M, Bhansali R, Moyo TK, Kenkre V, Ollila T, Hess B, Fitzgerald L, Shouse G, Davis JA, Jesme C, Pelcovits A, Moreira J, Lin A, Ma S, Winter JN, Danilov A, Barta SK, Gordon LI, Romancik J, Grover NS, Karmali R, American BiTE and CART Consortiu (2025). Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART. Cancers, 17(14),
  30. Neelapu S, Chavez J, Sehgal A, Epperla N, Ulrickson M, Bachy E, Munshi P, Casulo C, Maloney D, de Vos S, Reshef R, Leslie L, Oluwole O, Yakoub-Agha I, Khanal R, Rosenblatt J, Wulff J, Shen R, Zhang W, Poddar S, Miao H, Nikolajeva O, Jacobson (2025). Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. American journal of clinical oncology, 0(JCO-25-00668),
  31. Cappelli L, Kayne A, Newman J, Elguindy A, Epperla N, Palmer J, Outschoorn U, Porcu P, Shi W, Alnahhas (2025). Primary CNS Lymphoma: Predictors of Response to induction Therapy and Patterns of Progression. Neuro-oncology advances, 7,
  32. Olszewski AJ, Ollila TA, Chihara D, Shouse G, Grover N, Karmali R, Torka P, Thomas C, Geethakumari PR, Barta SK, Bartlett NL, Epperla (2025). Comparative effectiveness of immunotherapy alone or with chemotherapy as first-line treatment for marginal zone lymphoma. Haematologica,
  33. Mirza AS, Hosing C, Foss F, Kim S, Moskop A, Oloyede T, Abid MB, Afrough A, Ahmed S, Badar T, Barba P, Bhatt VR, Brown VI, Dahiya S, Deol A, Epperla N, Ganguly S, Grover NS, Hashmi H, Hashmi S, Hematti P, Hildebrandt GC, Hill JM Jr, Hossain NM, Ibrahim U, Johnson PC, Kharfan-Dabaja MA, Krem MM, Lekakis LJ, Maziarz RT, Murthy HS, Riedell PA, Salas MQ, Shouse G, Strouse C, Thakar MS, Turtle CJ, Woolfrey A, Wudhikarn K, Yared JA, Pasquini MC, Gowda (2025). Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas. Blood neoplasia, 3(2), 100187.
  34. Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson ML, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt JD, Wulff J, Shen RR, Zhang W, Poddar S, Miao H, Nikolajeva O, Jacobson C (2025). Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Journal of clinical oncology, 43(33), 3573-3577.
  35. Melody M, Epperla N, Shouse G, Romancik JT, Allen PB, Moyo TK, Kenkre VP, Ollila TA, Fitzgerald LA, Hess BT, David KA, Herr MM, Odetola O, Lin AY, Moreira J, Ma S, Winter JN, Roy I, Stephens DM, Danilov AV, Shah NN, Barta SK, Cortese MJ, Cohen J, Gordon LI, Karmali (2024). Subsequent Malignant Neoplasms in Patients Previously Treated with Anti-CD19 CAR T-Cell Therapy. Blood advances, 8(10), 2327-2331.
  36. Sayed A, Munir M, Ghazi SM, Ferdousi M, Krishan S, Shaaban A, Habib A, Kola-Kehinde O, Ruz P, Khan S, Sharma S, Meara A, Mahmood S, Feldman S, Yang EH, Kim J, Epperla N, Addison (2024). Cardiovascular toxicities associated with bispecific T-cell engager therapy. Journal for immunotherapy of cancer, 12(2),
  37. Iqbal M, Jagadeesh D, Chavez J, Khurana A, Rosenthal A, Craver E, Epperla N, Li Z, Isufi I, Awan FT, Dholaria BR, Maakaron JE, Sandoval-Sus JD, Mishra R, Saha A, Annunzio K, Bhaskar ST, Sumransub N, Fijalka A, Ivanov SA, Lin Y, Kharfan-Dabaja M (2024). Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy. Bone marrow transplantation, 59(2), 211-216.
  38. Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt J, Korn R, Peng W, Lui C, Wulff J, Shen R, Poddar S, Jung AS, Miao H, Beygi S, Jacobson C (2024). Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood, 143(6), 496-506.
  39. Rezazadeh A, Szabo A, Khurana A, Inwards DJ, Lunning MA, Bartlett NL, Caimi PF, Rodgers TD, Barr PM, Chowdhury SM, Epperla N, Mendries H, Hill BT, Oh TS, Karmali R, Chang JE, Goyal G, Parsons BM, Isaac KM, Portell CA, Monahan K, Siker M, King DM, Fenske T (2024). Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study. Haematologica, 109(5), 1439-1444.
  40. Epperla N, Zayac AS, Landsburg DJ, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman A, Li S, Medeiros LJ, Chang JE, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi Y, Bond DA, Evens AM, Naik SG, Kamdar M, Haverkos BM, Karmali R, Farooq U, Vose JM, Rubinstein P, Chaudhry A, Olszewski A (2024). High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series. Blood advances, 8(20), 5355-5364.
  41. Bommier C, Link BK, Gysbers BJ, Maurer MJ, Larson MC, Khurana A, Wang Y, Thompson CA, Chihara D, Alderuccio JP, Koff JL, Epperla N, Conconi A, Lossos IS, Nowakowski GS, Feldman AL, Habermann TM, King RL, Cerhan J (2024). Transformation in Marginal Zone Lymphoma: Results from a Prospective Cohort and a Meta-Analysis of the Literature. Blood advances, 8(23), 5939-5948.
  42. Epperla N, Huang Y, Cashen AF, Vaughn JL, Hanel W, Badar T, Barta SK, Caimi PF, Sethi TK, Reddy N, Karmali R, Bello C, Chavez JC, Kothari SK, Hernandez-Ilizaliturri FJ, Svoboda J, Lansigan F, Glenn MJ, Cohen JB, Sorge C, Christian B, Herrera AF, Hamadani M, Costa LJ, Xavier A (2024). Evaluation of prognostic factors for high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood advances, 8(21), 5458-5466.
  43. Karmali R, Machhi R, Epperla N, Shouse G, Romancik J, Moyo TK, Kenkre V, Ollila TA, Fitzgerald L, Hess B, David K, Roy I, Zurko J, Chowdhury SM, Annunzio K, Ferdman R, Bhansali RS, Harris EI, Liu J, Nizamuddin I, Ma S, Moreira J, Winter J, Pro B, Stephens DM, Danilov A, Shah NN, Cohen JB, Barta SK, Torka P, Gordon L (2024). Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy. Blood advances, 8(10), 2592-2599.
  44. Grover NS, Annunzio K, Watkins M, Torka P, Karmali R, Anampa-Guzmán A, Oh TS, Reves H, Tavakkoli M, Hansinger E, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Shouse G, Olszewski AJ, Epperla (2024). Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study. Blood cancer journal, 14(1), 182.
  45. Munir M, Sayed A, Addison D, Epperla (2024). Cardiovascular Toxicities Associated with Novel Cellular Immune Therapies. Blood advances, 8(24), 6282-6296.
  46. Bajwa A, Zhao Q, Geer MJ, Lin C, Westholder J, Maakaron J, Ghosh M, Frame DG, Galal A, Tossey J, Ahmed N, Bezerra ED, Denlinger N, de Lima MJ, Epperla N, Caimi PF, Voorhees TJ (2024). Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Related CRS and ICANS - A Multicenter Retrospective Analysis. Blood Advances,
  47. Vaughn JL, Ramdhanny A, Munir M, Rimmalapudi S, Epperla (2024). A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study. Blood cancer journal, 14(1), 212.
  48. Epperla N, Lucero M, Bailey T, Mirams L, Cheung J, Amet M, Milligan G, Chen (2024). Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma. Blood cancer journal, 14(1), 210.
  49. Aqeel SB, Faisal MS, Akhtar OS, Attwood K, George A, Advani P, Epperla N, Torka (2024). Racial and ethnic disparities in outcomes of diffuse large B cell lymphoma in adolescent and young adults: a SEER database analysis. Annals of hematology & oncology,
  50. Annunzio K, Bhatta S, Hanel W, Zhao Q, Owen M, Rosen H, Voorhees TJ, Bond DA, Sawalha Y, Sigmund AM, Alinari L, Baiocchi RA, Maddocks KJ, Jones D, Christian B, Epperla (2024). Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients. Hematological oncology, 42(3), e3278.
  51. Denlinger N, Song NJ, Zhang X, Jeon H, Peterson C, Wang Y, Reynolds K, Bolz RM, Miao J, Song C, Wu D, Chan WK, Bezerra E, Epperla N, Voorhees TJ, Brammer J, Kittai AS, Bond DA, Sawalha Y, Sigmund A, Reneau JC, Rubinstein MP, Hanel W, Christian B, Baiocchi RA, Maddocks K, Alinari L, Vasu S, de Lima M, Chung D, Jaglowski S, Li Z, Huang X, Yang (2024). Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma. Blood advances, 8(12), 3140-3153.
  52. Wang TP, Ahn KW, Shadman M, Kaur M, Ahmed N, Bacher U, Cerny J, Chen A, Epperla N, Frigault M, Grover N, Haverkos B, Hill B, Hossain N, Iqbal M, Jain T, Krem MM, Maakaron J, Modi D, Alhaj Moustafa M, Riedell P, Savani B, Sica RA, Sureda A, Wudhikarn K, Herrera AF, Sauter C, Hamadani M, Jimenez Jimenez (2024). Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis. Leukemia, 38(7), 1564-1569.
  53. Epperla N, Hashmi H, Ahn KW, Allbee-Johnson M, Chen AI, Wirk B, Kanakry JA, Lekakis L, Kharfan-Dabaja MA, Scordo M, Riedell PA, Jain T, Shadman M, Sauter C, Hamadani M, Herrera AF, Ahmed (2024). Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis. British journal of haematology, 205(3), 1202-1207.
  54. Kapoor N, Zhao Q, Stiff A, Bhat SA, Anghelina MI, Andritsos LA, Blachly JS, Epperla N, Boghdadly ZE, Grever MR, Rogers K (2024). Incidence, description, and timing of serious and opportunistic infections in patients with hairy cell leukemia. EJHaem, 5(5), 1005-1009.
  55. Aqeel SB, Faisal MS, Akhtar OS, Attwood K, George A, Advani P, Epperla N, Torka (2024). Racial and ethnic disparities in outcomes of diffuse large B cell lymphoma in adolescent and young adults: a SEER database analysis. Annals of hematology, 103(12), 5539-5547.
  56. Kenkre VP, Lin Y, Epperla N, Rajguru SA, Chang JE, Pophali PA, Harris EI, Fletcher CD, Matasar M, Eltoukhy H, Bond DA, Sawalha Y, Christian B, Voorhees T, Endres M, Howard M, Bhavsar D, Fleming M, Carter JS, Evens A (2024). A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study. Blood (2024), 144(Supplement 1), 4415.
  57. Saverno K, Savill KMZ, Feinberg B, Galvin J, Pathak P, Amoloja T, Epperla N, Nastoupil L (2024). Real-World Use of Tafasitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States by Primary Refractory Status. Hematology, transfusion and cell therapy, 46(Supplement 4), S229.
  58. Epperla N, Nastoupil LJ, Savill KMZ, Feinberg B, Galvin J, Pathak P, Amoloja T, Vukcevic M, Saverno (2024). Real-World Use of Tafasitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States by Age Group (>70 Years and 70 Years). Hematology, transfusion and cell therapy, 46(Supplement 4), S226-S227.
  59. Epperla N, Nastoupil LJ, Feinberg B, Galvin J, Pathak P, Amoloja T, Gentile D, Saverno (2024). Real-World Sequential use of CD19-Directed Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Tafasitamab Preceding Chimeric Antigen Receptor T-Cell Therapy. Hematology, transfusion and cell therapy, 46(Supplement 4), S226.
  60. Cappelli L, Kayne A, Newman J, Sharif M, Elguindy A, Epperla N, Palmer J, Alnahhas I, Shi (2024). Patterns of Disease Progression in patients with newly diagnosed Primary Central Nervous System Lymphoma Following Treatment with High-Dose Methotrexate. Research square, Preprint Version 1,
  61. Zurko J, Nizamuddin I, Epperla N, David K, Cohen JB, Moyo TK, Ollila T, Hess B, Roy I, Ferdman R, Liu J, Chowdhury SM, Romancik J, Bhansali RS, Harris EI, Sorrell M, Masel R, Kittai AS, Denlinger N, Sigmund AM, Fitzgerald L, Galvez C, Ma S, Winter J, Pro B, Gordon LI, Danilov A, Stephens D, Shah NN, Kenkre V, Barta SK, Torka P, Shouse G, Karmali R (2023). Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL. Blood Adv, 7(12), 2657-2669.
  62. Epperla N, Reljic T, Chowdhury SM, Ferreri AJM, Kumar A, Hamadani M (2023). Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta-analysis. Hematol Oncol, 41(1), 88-96.
  63. Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan XC, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Oh TS, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G (2023). Postibrutinib relapse outcomes for patients with marginal zone lymphoma. Blood Adv, 7(1), 88-91.
  64. Annunzio K, Cackovic M, Bond D, Sawalha Y, Voorhees TJ, Hanel W, Alinari L, Baiocchi R, Reneau J, Brammer J, Maddocks K, Christian B, Epperla N (2023). Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy. Blood Adv, 7(10), 2241-2244.
  65. Epperla N, Switchenko J, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Hamadani M, Fenske TS, Martin P, Malecek MK, Kahl BS, Flowers CR, Link BK, Kaplan LD, Inwards DJ, Feldman AL, Hsi ED, Maddocks K, Blum KA, Bartlett NL, Cerhan JR, Leonard JP, Habermann TM, Maurer MJ, Cohen JB (2023). Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood Adv, 7(11), 2287-2296.
  66. Azar JH, Evans JP, Sikorski MH, Chakravarthy KB, McKenney S, Carmody I, Zeng C, Teodorescu R, Song NJ, Hamon JL, Bucci D, Velegraki M, Bolyard C, Weller KP, Reisinger SA, Bhat SA, Maddocks KJ, Denlinger N, Epperla N, Gumina RJ, Vlasova AN, Oltz EM, Saif LJ, Chung D, Woyach JA, Shields PG, Liu SL, Li Z, Rubinstein MP (2023). Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapy. JCI Insight, 8(6).
  67. Faisal MS, Hanel W, Voorhees T, Li R, Huang Y, Khan A, Bond D, Sawalha Y, Reneau J, Alinari L, Baiocchi R, Christian B, Maddocks K, Efebera Y, Penza S, Saad A, Brammer J, DeLima M, Jaglowski S, Epperla N (2023). Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents. Cancer Med, 12(7), 8228-8237.
  68. Hanel W, Shindiapina P, Bond DA, Sawalha Y, Epperla N, Voorhees T, Welkie RL, Huang Y, Behbehani GK, Zhang X, McLaughlin E, Chan WK, Brammer JE, Jaglowski S, Reneau JC, Christian BA, William BM, Cohen JB, Baiocchi RA, Maddocks K, Blum KA, Alinari L (2023). A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma. Cancers (Basel), 15(5).
  69. Agrawal P, David KA, Chen Z, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, Malecek MK, Carter J, Zayac A, Kim MS, Reddy N, Ney D, Habib A, Strouse C, Graber J, Bachanova V, Salman S, Vendiola JA, Hossain N, Tsang M, Major A, Gandhi MK, Keane C, Bond DA, Folstad M, Chang J, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Berg S, Glantz M, Goldlust SA, Matnani R, Kumar P, Ollila TA, Cai J, Spurgeon SE, Sieg AG, Cleveland J, Epperla N, Karmali R, Naik S, Smith SM, Rubenstein JL, Kahl BS, Chadburn A, Evens AM, Martin P (2023). EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. Leuk Lymphoma, 64(5), 1026-1034.
  70. David KA, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, Malecek MK, Carter J, Zayac A, Kim MS, Reddy N, Ney D, Habib A, Strouse C, Graber J, Bachanova V, Salman S, Vendiola JA, Hossain N, Tsang M, Major A, Bond DA, Agrawal P, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Berg S, Glantz M, Goldlust SA, Folstad M, Kumar P, Ollila TA, Cai J, Spurgeon S, Sieg A, Cleveland J, Chang J, Epperla N, Karmali R, Naik S, Martin P, Smith SM, Rubenstein J, Kahl B, Evens AM (2023). Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers. Am J Hematol, 98(6), 900-912.
  71. McKenna M, Epperla N, Ghobadi A, Liu J, Lazaryan A, Ibrahim U, Jacobson CA, Naik SG, Nastoupil L, Chowdhury SM, Voorhees TJ, Jacobs MT, Farooq U, Osman K, Olszewski AJ, Ahmed S, Evens AM (2023). Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD. Br J Haematol, 202(2), 248-255.
  72. Epperla N, Zhao Q, Karmali R, Torka P, Shea L, Oh TS, Anampa-Guzmán A, Reves H, Tavakkoli M, Greenwell IB, Hansinger E, Umyarova E, Annunzio K, Sawalha Y, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Grover NS, Olszewski A (2023). Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study. Blood advances, 7(17), 5038-5046.
  73. Epperla N, Kumar A, Abutalib SA, Awan FT, Chen YB, Gopal AK, Holter-Chakrabarty J, Kekre N, Lee CJ, Lekakis L, Lin Y, Mei M, Nathan S, Nastoupil L, Oluwole O, Phillips AA, Reid E, Rezvani AR, Trotman J, Zurko J, Kharfan-Dabaja MA, Sauter CS, Perales MA, Locke FL, Carpenter PA, Hamadani (2023). ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma. Transplantation and cellular therapy, 29(9), 548-555.
  74. Sircar A, Singh S, Xu-Monette ZY, Coyle KM, Hilton LK, Chavdoula E, Ranganathan P, Jain N, Hanel W, Tsichlis P, Alinari L, Peterson BR, Tao J, Muthusamy N, Baiocchi R, Epperla N, Young KH, Morin R, Sehgal (2023). Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma. Leukemia, 37(10), 2094-2106.
  75. Bowers JT, Anna J, Bair SM, Annunzio K, Epperla N, Pullukkara JJ, Gaballa S, Spinner MA, Li S, Messmer MR, Nguyen J, Ayers EC, Wagner CB, Hu B, Di M, Huntington SF, Furqan F, Shah NN, Chen C, Ballard HJ, Hughes ME, Chong EA, Nasta SD, Barta SK, Landsburg DJ, Svoboda (2023). Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort. Blood advances, 7(21), 6630-6638.
  76. Steiner RE, Hwang SR, Khurana A, Habermann TM, Epperla N, Annunzio K, Allen PB, Baird K, Paulino D, Alderuccio JP, Lossos IS, David K, Evens AM, Pandya K, Bair SM, Kamdar M, Ba Aqeel S, Torka P, Lynch R, Smith S, Feng L, Noorani M, Ahmed S, Nair R, Vega F, Wu S, Fang P, Pinnix CC, Gunther JR, Dabaja BS, Lee H (2023). Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma. Blood advances, 7(24), 7485-7493.
  77. Dhir A, Epperla N, Costa LJ, Xavier A (2023). Nonbiological factors affecting outcomes in adolescents and young adults with lymphoma. Frontiers in public health, 11, 1261066.
  78. Annunzio K, Grover NS, Welkie RL, Torka P, Watkins MP, Anampa-Guzmán A, Tavakkoli M, Oh TS, Reves H, Jones D, Hanel W, Christian B, Ramakrishnan Geethakumari P, Karmali R, Barta SK, Bartlett NL, Olszewski AJ, Epperla (2023). Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study. Blood advances, 7(22), 6839-6843.
  79. Nalin A, Zhao Q, Voorhees T, Bond D, Sawalha Y, Hanel W, Sigmund A, Annunzio K, Alinari L, Baiocchi R, Maddocks K, Jones D, Christian B, Epperla (2023). Impact of circulating lymphoma cells at diagnosis on outcomes in patients with Waldenstrom macroglobulinemia. Frontiers in oncology, 13, 1264387.
  80. Annunzio K, Grover NS, Welkie RL, Torka P, Watkins MP, Anampa-Guzman A, Tavakkoli M, Oh TS, Reves H, Jones D, Hanel W, Christian B, Geethakumari PR, Karmali R, Barta SK, Bartlett NL, Olszewski AJ, Epperla (2023). Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study. Blood Advances, (2023) 7 (22), 6839-6843.
  81. Zayac AS, Landsburg DJ, Hughes ME, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Epperla N, Bond DA, Farooq U, Saad M, Evens AM, Pandya K, Naik SG, Kamdar M, Haverkos B, Karmali R, Oh TS, Vose JM, Nutsch H, Rubinstein PG, Chaudhry A, Olszewski A (2023). High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood advances, 7(21), 6381-6394.
  82. Epperla N, Zhao Q, Karmali R, Torka P, Shea L, Oh TS, Anampa-Guzmán A, Reves H, Tavakkoli M, Greenwell IB, Hansinger E, Umyarova E, Annunzio K, Sawalha Y, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Grover NS, Olszewski A (2023). Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study. Blood advances, 7(17), 5038-5046.
  83. Phelan R, Im A, Hunter RL, Inamoto Y, Lupo-Stanghellini MT, Rovo A, Badawy SM, Burns L, Eissa H, Murthy HS, Prasad P, Sharma A, Suelzer E, Agrawal V, Aljurf M, Baker K, Basak GW, Buchbinder D, DeFilipp Z, Grkovic LD, Dias A, Einsele H, Eisenberg ML, Epperla N, Farhadfar N, Flatau A, Gale RP, Greinix H, Hamilton BK, Hashmi S, Hematti P, Jamani K, Maharaj D, Murray J, Naik S, Nathan S, Pavletic S, Peric Z, Pulanic D, Ross R, Salonia A, Sanchez-Ortega I, Savani BN, Schechter T, Shah AJ, Smith SM, Snowden JA, Steinberg A, Tremblay D, Vij SC, Walker L, Wolff D, Yared JA, Schoemans H, Tichelli A (2022). Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Bone Marrow Transplant, 57(7), 1150-1163.
  84. Ahmed S, Zhao Q, Hanel W, Qazilbash MH, Patel K, Narra R, Kansagra A, Iqbal M, Awan FT, Christian B, Jaglowski SM, Kharfan-Dabaja MA, Hamadani M, Epperla N (2022). Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. Hematol Oncol, 40(1), 48-56.
  85. Fleming M, Huang Y, Dotson E, Bond DA, Reneau J, Epperla N, Alinari L, Brammer J, Christian BA, Baiocchi RA, Maddocks K, Sawalha Y (2022). Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas. Blood Adv, 6(2), 460-472.
  86. Alderuccio JP, Arcaini L, Watkins MP, Beaven AW, Shouse G, Epperla N, Spina M, Stefanovic A, Sandoval-Sus J, Torka P, Alpert AB, Olszewski AJ, Kim SH, Hess B, Gaballa S, Ayyappan S, Castillo JJ, Argnani L, Voorhees TJ, Saba R, Chowdhury SM, Vargas F, Reis IM, Kwon D, Alexander JS, Zhao W, Edwards D, Martin P, Cencini E, Kamdar M, Link BK, Logothetis CN, Herrera AF, Friedberg JW, Kahl BS, Luminari S, Zinzani PL, Lossos IS (2022). An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Adv, 6(7), 2035-2044.
  87. Voorhees TJ, Epperla N (2022). Identifying aggressive subsets within diffuse large B-cell lymphoma: implications for treatment approach. Expert Rev Anticancer Ther, 22(5), 523-533.
  88. Phelan R, Im A, Hunter RL, Inamoto Y, Lupo-Stanghellini MT, Rovo A, Badawy SM, Burns L, Eissa H, Murthy HS, Prasad P, Sharma A, Suelzer E, Agrawal V, Aljurf M, Baker K, Basak GW, Buchbinder D, DeFilipp Z, Grkovic LD, Dias A, Einsele H, Eisenberg ML, Epperla N, Farhadfar N, Flatau A, Gale RP, Greinix H, Hamilton BK, Hashmi S, Hematti P, Jamani K, Maharaj D, Murray J, Naik S, Nathan S, Pavletic S, Peric Z, Pulanic D, Ross R, Salonia A, Sanchez-Ortega I, Savani BN, Schechter T, Shah AJ, Smith SM, Snowden JA, Steinberg A, Tremblay D, Vij SC, Walker L, Wolff D, Yared JA, Schoemans H, Tichelli A (2022). Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Transplant Cell Ther, 28(6), 335.e1-335.e17.
  89. Anghelina M, Naughton MJ, Zhao Q, Ruppert AS, Neal J, Rogers KA, Blachly JS, Lozanski G, Bhat SA, Kraut E, Epperla N, Mathur P, Zent CS, Banerji V, Dearden C, Hutchinson T, Grever M, Andritsos LA (2022). Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemia. Leuk Res, 120, 106919.
  90. Fleming M, Huang Y, Dotson E, Bond DA, Reneau J, Epperla N, Alinari L, Brammer J, Christian B, Baiocchi RA, Maddocks K, Sawalha Y (2022). Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study. Ther Adv Hematol, 13, 20406207221112900.
  91. Andritsos LA, Anghelina M, Neal J, Blachly JS, Mathur P, Lele O, Dearden C, Iyengar S, Cross M, Zent CS, Rogers KA, Epperla N, Lozanski G, Oakes CC, Kraut E, Ruppert AS, Zhao Q, Bhat SA, Forconi F, Banerji V, Handunnetti S, Tam CS, Seymour JF, Else M, Kreitman RJ, Saven A, Call T, Parikh SA, Ravandi F, Johnston JB, Tiacci E, Troussard X, Tallman MS, Dietrich S, Tadmor T, Gozzetti A, Zinzani PL, Robak T, Quest G, Demeter J, Rai K, Fernandez SA, Grever M (2022). Development of a distributed international patient data registry for hairy cell leukemia. Leuk Lymphoma, 63(13), 3021-3031.
  92. Ravandi F, Kreitman RJ, Tiacci E, Andritsos L, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call T, Chihara D, Dearden C, Demeter J, Dietrich S, Else M, Epperla N, Falini B, Forconi F, Gladstone DE, Gozzetti A, Iyengar S, Johnston JB, Jorgensen J, Juliusson G, Lauria F, Lozanski G, Parikh SA, Park JH, Polliack A, Quest G, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Thompson PA, Troussard X, Zent CS, Zenz T, Zinzani PL, Wörmann B, Rai K, Grever M (2022). Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer J, 12(12), 165.
  93. Evens AM, Danilov A, Jagadeesh D, Sperling A, Kim SH, Vaca R, Wei C, Rector D, Sundaram S, Reddy N, Lin Y, Farooq U, D'Angelo C, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Yazdy M, Rabinovich E, Varma G, Karmali R, Mian A, Savani M, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein AK, Blum KA, Boughan KM, Smith SE, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Ramdial J, Maliske SM, Epperla N, Venugopal P, Feldman TA, Smith SD, Stadnik A, David KA, Naik S, Lossos IS, Lunning MA, Caimi P, Kamdar M, Palmisiano N, Bachanova V, Portell CA, Phillips T, Olszewski AJ, Alderuccio JP (2021). Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood, 137(3), 374-386.
  94. Epperla N, Ahn KW, Khanal M, Litovich C, Ahmed S, Ghosh N, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M (2021). Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. Transplant Cell Ther, 27(1), 58-66.
  95. Olszewski AJ, Jakobsen LH, Collins GP, Cwynarski K, Bachanova V, Blum KA, Boughan KM, Bower M, Dalla Pria A, Danilov A, David KA, Diefenbach C, Ellin F, Epperla N, Farooq U, Feldman TA, Gerrie AS, Jagadeesh D, Kamdar M, Karmali R, Kassam S, Kenkre VP, Khan N, Kim SH, Klein AK, Lossos IS, Lunning MA, Martin P, Martinez-Calle N, Montoto S, Naik S, Palmisiano N, Peace D, Phillips EH, Phillips TJ, Portell CA, Reddy N, Santarsieri A, Sarraf Yazdy M, Smeland KB, Smith SE, Smith SD, Sundaram S, Zayac AS, Zhang XY, Zhu C, Cheah CY, El-Galaly TC, Evens AM (2021). Burkitt Lymphoma International Prognostic Index. J Clin Oncol, 39(10), 1129-1138.
  96. Zayac AS, Evens AM, Danilov A, Smith SD, Jagadeesh D, Leslie LA, Wei C, Kim SH, Naik S, Sundaram S, Reddy N, Farooq U, Kenkre VP, Epperla N, Blum KA, Khan N, Singh D, Alderuccio JP, Godara A, Yazdy MS, Diefenbach C, Rabinovich E, Varma G, Karmali R, Shao Y, Trabolsi A, Burkart M, Martin P, Stettner S, Chauhan A, Choi YK, Straker-Edwards A, Klein A, Churnetski MC, Boughan KM, Berg S, Haverkos BM, Orellana-Noia VM, D'Angelo C, Bond DA, Maliske SM, Vaca R, Magarelli G, Sperling A, Gordon MJ, David KA, Savani M, Caimi P, Kamdar M, Lunning MA, Palmisiano N, Venugopal P, Portell CA, Bachanova V, Phillips T, Lossos IS, Olszewski AJ (2021). Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. Haematologica, 106(7), 1932-1942.
  97. Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, Epperla N, Rock AD, Lee J, Petti AA, Soon-Shiong P, Fehniger TA (2021). Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Clin Cancer Res, 27(12), 3339-3350.
  98. Vaughn JL, Spies D, Xavier AC, Epperla N (2021). Racial disparities in the survival of patients with indolent non-Hodgkin lymphomas in the United States. Am J Hematol, 96(7), 816-822.
  99. Choueiry F, Singh S, Sircar A, Laliotis G, Sun X, Chavdoula E, Zhang S, Helmig-Mason J, Hart A, Epperla N, Tsichlis P, Baiocchi R, Alinari L, Zhu J, Sehgal L (2021). Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma. Cancers (Basel), 13(9).
  100. Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS (2021). Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. JAMA Oncol, 7(7), 993-1003.
  101. Shanmugasundaram K, Goyal S, Switchenko J, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Epperla N, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Kahl BS, Martin P, Guo J, Flowers CR, Cohen JB (2021). Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. Eur J Haematol, 107(3), 301-310.
  102. Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, Hamadani M, Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen JB (2021). Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. Am J Hematol, 96(11), 1374-1384.
  103. D'Angelo CR, Hanel W, Chen Y, Yu M, Yang D, Guo L, Karmali R, Burkart M, Ciccosanti C, David K, Risch Z, Murga-Zamalloa C, Devata S, Wilcox R, Savani M, Courville EL, Bachanova V, Rabinovich E, Peace D, Osman F, Epperla N, Kenkre VP (2021). Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysis. Hematol Oncol, 39(4), 473-482.
  104. Vaughn JL, Soroka O, Epperla N, Safford M, Pinheiro LC (2021). Racial and ethnic differences in the utilization of autologous transplantation for lymphoma in the United States. Cancer Med, 10(20), 7330-7338.
  105. Bond DA, Switchenko JM, Villa D, Maddocks K, Churnetski M, Gerrie AS, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Hill BT, Sawalha Y, Martin P, Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Ghosh N, Park SI, Epperla N, Badar T, Guo J, Hamadani M, Fenske TS, Malecek MK, Kahl BS, Flowers CR, Blum KA, Cohen JB (2021). Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood Adv, 5(23), 5179-5189.
  106. Riedell PA, Hamadani M, Ahn KW, Litovich C, Brunstein CG, Cashen AF, Cohen JB, Epperla N, Hill BT, Im A, Inwards DJ, Lister J, McCarty JM, Ravi Kiran Pingali S, Shadman M, Shaughnessy P, Solh M, Stiff PJ, Vose JM, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM (2021). Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. Br J Haematol, 195(5), 757-763.
  107. Alderuccio JP, Olszewski AJ, Evens AM, Collins GP, Danilov AV, Bower M, Jagadeesh D, Zhu C, Sperling A, Kim SH, Vaca R, Wei C, Sundaram S, Reddy N, Dalla Pria A, D'Angelo C, Farooq U, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Kassam S, Yazdy M, Rabinovich E, Post FA, Varma G, Karmali R, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein A, Blum KA, Boughan KM, Mian A, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Maliske SM, Epperla N, Caimi P, Smith SE, Kamdar M, Venugopal P, Feldman TA, Rector D, Smith SD, Stadnik A, Portell CA, Lin Y, Naik S, Montoto S, Lossos IS, Cwynarski (2021). HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Blood advances, 5(14), 2852-2862.
  108. Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, Epperla N, Rock AD, Lee J, Petti AA, Soon-Shiong P, Fehniger T (2021). Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Clinical cancer research, 27(12), 3339-3350.
  109. Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, Hamadani M, Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen J (2021). Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. American journal of hematology, 96(11), 1374-1384.
  110. Badar T, Epperla N, Szabo A, Borson S, Vaughn J, George G, Saini N, Shah AR, Patel RD, Ahmed S, Shah NN, Cashen AF, Hamadani M, Fenske TS (2020). Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv, 4(1), 47-54.
  111. Jagadeesh D, Majhail NS, He Y, Ahn KW, Litovich C, Ahmed S, Aljurf M, Bacher U, Badawy SM, Bejanyan N, Cairo M, Cerny J, Epperla N, Farhadfar N, Freytes CO, Gale RP, Haverkos B, Hossain N, Inwards D, Kamble RT, Kenkre VP, Lazarus HM, Lazaryan A, Lekakis L, Mei M, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Ramakrishnan Geethakumari P, Savani BN, Yared JA, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M (2020). Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer, 126(10), 2279-2287.
  112. Epperla N, Pavilack M, Olufade T, Bashyal R, Li J, Kabadi SM, Yuce H, Andritsos L (2020). Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: a US population-retrospective claims analysis. Orphanet J Rare Dis, 15(1), 47.
  113. Palmer JD, Bhamidipati D, Shukla G, Epperla N, Glass J, Kim L, Shi W (2020). Outcomes after stereotactic radiosurgery for CNS lymphoma. J Neurooncol, 147(2), 465-476.
  114. Epperla N, Li A, Logan B, Fretham C, Chhabra S, Aljurf M, Chee L, Copelan E, Freytes CO, Hematti P, Lazarus HM, Litzow M, Nishihori T, Olsson RF, Prestidge T, Saber W, Wirk B, Yared JA, Loren A, Pasquini M (2020). Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. Br J Haematol, 189(6), 1171-1181.
  115. Epperla N (2020). What is the optimal reduced-intensity conditioning regimen for patients with classical Hodgkin lymphoma undergoing allogeneic transplantation? - is there a one to use or avoid. Br J Haematol, 190(4), 490-492.
  116. Ghosh N, Ahmed S, Ahn KW, Khanal M, Litovich C, Aljurf M, Bacher VU, Bredeson C, Epperla N, Farhadfar N, Freytes CO, Ganguly S, Haverkos B, Inwards D, Kamble RT, Lazarus HM, Lekakis L, Murthy HS, Nishihori T, Ramakrishnan P, Rizzieri DA, Yared JA, Kharfan-Dabaja MA, Sureda A, Hamadani M (2020). Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. JAMA Oncol, 6(7), 1011-1018.
  117. Epperla N, Vaughn JL, Othus M, Hallack A, Costa LJ (2020). Recent survival trends in diffuse large B-cell lymphoma--Have we made any progress beyond rituximab? Cancer Med, 9(15), 5519-5525.
  118. Thangavadivel S, Zhao Q, Epperla N, Rike L, Mo X, Badawi M, Bystry DM, Phelps MA, Andritsos LA, Rogers KA, Jones J, Woyach JA, Byrd JC, Awan FT (2020). Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. Clin Cancer Res, 26(23), 6187-6195.
  119. Badar T, Hamadani M, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, Epperla N, Chhabra S, Xavier AC, Karmali R, Salhab M, Reddy N, Glenn MJ, Hernandez-Ilizaliturri FJ, Flowers CR, Evens AM, Zhou Z, Lansigan F, Barta SK, Cohen JB, Fenske TS, Costa LJ (2019). Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. Leuk Lymphoma, 60(4), 940-946.
  120. Shah NN, Szabo A, Saba R, Strelec L, Kodali D, Vaughn JL, Esan O, Yang DT, Mato AR, Kanate AS, Olteanu H, Hamadani M, Fenske TS, Kenkre VP, Svoboda J, Cashen AF, Epperla N (2019). Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. Clin Lymphoma Myeloma Leuk, 19(2), 95-102.
  121. Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M (2019). Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol, 12(1), 6.
  122. Epperla N, Shana'ah AY, Jones D, Christian BA, Ayyappan S, Maddocks K, Woyach JA (2019). Resistance mechanism for ibrutinib in marginal zone lymphoma. Blood Adv, 3(4), 500-502.
  123. Guo S, Jiang S, Epperla N, Ma Y, Maadooliat M, Ye Z, Olson B, Wang M, Kitchner T, Joyce J, An P, Wang F, Strenn R, Mazza JJ, Meece JK, Wu W, Jin L, Smith JA, Wang J, Schrodi SJ (2019). A gene-based recessive diplotype exome scan discovers FGF6, a novel hepcidin-regulating iron-metabolism gene. Blood, 133(17), 1888-1898.
  124. Epperla N, Badar T, Szabo A, Vaughn J, Borson S, Saini NY, Patel RD, Shah NN, Hamadani M, Ahmed S, Cashen AF, Fenske TS (2019). Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. Blood Adv, 3(11), 1661-1669.
  125. Epperla N, Hamadani M, Reljic T, Kharfan-Dabaja MA, Savani BN, Kumar A (2019). Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis. Cancer, 125(24), 4417-4425.
  126. Epperla N, Ahn KW, Armand P, Jaglowski S, Ahmed S, Kenkre VP, Savani B, Jagasia M, Shah NN, Fenske TS, Sureda A, Smith SM, Hamadani M (2018). Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. Biol Blood Marrow Transplant, 24(1), 78-85.
  127. Xavier AC, Epperla N, Taub JW, Costa LJ (2018). Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults. Am J Hematol, 93(2), 238-245.
  128. Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J (2018). R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol, 180(4), 534-544.
  129. Epperla N, Hamadani M, Ahn KW, He F, Kodali D, Kleman A, Hari PN, Pasquini M, Fenske TS, Craig MD, Kanate AS, Bachanova V (2018). Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant, 24(5), 983-988.
  130. Greenwell IB, Staton AD, Lee MJ, Switchenko JM, Saxe DF, Maly JJ, Blum KA, Grover NS, Mathews SP, Gordon MJ, Danilov AV, Epperla N, Fenske TS, Hamadani M, Park SI, Flowers CR, Cohen JB (2018). Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer, 124(11), 2306-2315.
  131. Shah NN, Ahn KW, Litovich C, Fenske TS, Ahmed S, Battiwalla M, Bejanyan N, Dahi PB, Bolaños-Meade J, Chen AI, Ciurea SO, Bachanova V, DeFilipp Z, Epperla N, Farhadfar N, Herrera AF, Haverkos BM, Holmberg L, Hossain NM, Kharfan-Dabaja MA, Kenkre VP, Lazarus HM, Murthy HS, Nishihori T, Rezvani AR, D'Souza A, Savani BN, Ulrickson ML, Waller EK, Sureda A, Smith SM, Hamadani M (2018). Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood Adv, 2(8), 933-940.
  132. Calzada O, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov A, Epperla N, Fenske TS, Hamadani M, Flowers CR, Cohen JB (2018). Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. Leuk Lymphoma, 59(12), 2862-2870.
  133. Strouse C, Epperla N (2017). A rash diagnosis: Gemcitabine-associated pseudocellulitis. J Oncol Pharm Pract, 23(2), 157-160.
  134. Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ, Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, Hamadani M (2017). Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. Am J Hematol, 92(2), 161-170.
  135. Dang G, Epperla N, Muppidi V, Sahr N, Pan A, Simpson P, Baumann Kreuziger L (2017). Medical Management of Pump-Related Thrombosis in Patients with Continuous-Flow Left Ventricular Assist Devices: A Systematic Review and Meta-Analysis. ASAIO J, 63(4), 373-385.
  136. Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS (2017). Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. Hematol Oncol, 35(4), 528-535.
  137. Dhakal B, Fenske TS, Ramalingam S, Shuff J, Epperla N, Hosking P, Rein L, Banerjee A, Hari P, D'Souza A, Shah N, Siker M, Griepentrog GJ, Harris GJ, Wells TS, Erickson BA, Hamadani M (2017). Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. Clin Lymphoma Myeloma Leuk, 17(5), 305-311.e2.
  138. Epperla N, Pham AQ, Burnette BL, Wiseman GA, Habermann TM, Macon WR, Ansell SM, Inwards DJ, Micallef IN, Johnston PB, Markovic SN, Porrata LF, Colgan JP, Ristow KM, Nowakowski GS, Witzig TE (2017). Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. Br J Haematol, 178(3), 427-433.
  139. Kapke JT, Epperla N, Shah N, Richardson K, Carrum G, Hari PN, Pingali SR, Hamadani M, Karmali R, Fenske TS (2017). Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk, 17(7), 408-414.
  140. Epperla N, Ye F, Idris A, Sakkalaek A, Liang H, Chyou PH, Dart RA, Mazza J, Yale S (2017). Treatment-Related Cardiovascular Outcomes in Patients with Symptomatic Subclavian Artery Stenosis. Cureus, 9(5), e1262.
  141. Epperla N, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani AR, Smith SM, Sureda A, Fenske TS, Kharfan-Dabaja MA, Armand P, Hamadani M (2017). Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. J Hematol Oncol, 10(1), 117.
  142. Epperla N, Hemauer K, Hamadani M, Friedman KD, Kreuziger LB (2017). Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy. Transfusion, 57(11), 2775-2781.
  143. Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evens AM, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ (2017). C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. Cancer, 123(22), 4411-4418.
  144. Kapke JT, Epperla N, Shah N, Richardson K, Carrum G, Hari PN, Pingali SR, Hamadani M, Karmali R, Fenske T (2017). Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. Clinical lymphoma, myeloma & leukemia, 17(7), 408-414.
  145. Epperla N, George B (2016). An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer. J Gastrointest Cancer, 47(2), 206-9.
  146. Epperla N, Hemauer K, Friedman KD, George JN, Foy P (2016). Congenital thrombotic thrombocytopenic purpura related to a novel mutation in ADAMTS13 gene and management during pregnancy. Am J Hematol, 91(6), 644-6.
  147. Epperla N, Strouse C, VanSandt AM, Foy P (2016). Difficult to swallow: warm autoimmune hemolytic anemia in a Jehovah's Witness treated with hemoglobin concentrate complicated by achalasia. Transfusion, 56(7), 1801-6.
  148. Epperla N, Weissman DE (2016). Chemotherapy: Response and Survival Data #99. J Palliat Med, 19(9), 1011.
  149. Epperla N, Harrington AM, Hemauer K, Shah NN (2016). Extracavitary primary effusion lymphoma associated with hemophagocytic lymphohistiocytosis. Am J Hematol, 91(11), 1161-1164.
  150. Raj RV, Hari P, Pasquini M, Epperla N, D'Souza A, Fenske T, Shaw BE, Rizzo JD, Drobyski W, Hamadani M (2016). Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. Bone Marrow Transplant, 51(12), 1602-1604.
  151. Epperla N, Olteanu H, Hamadani M (2016). Think outside the box: Acanthamoeba encephalitis following autologous haematopoietic stem cell transplantation. Br J Haematol, 175(5), 758.
  152. Epperla N, Shah N, Hamadani M, Richardson K, Kapke JT, Patel A, Teegavarapu SP, Carrum G, Hari PN, Pingali SR, Karmali R, Fenske TS (2016). Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk, 16(12), 672-678.
  153. Epperla N, Hocking W (2015). Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia. Clin Med Res, 13(1), 32-5.
  154. Epperla N, Kattamanchi S, Fritsche TR (2015). Appearances are Deceptive: Staphylococcus Superinfection of Clavicular Tuberculous Osteomyelitis. Clin Med Res, 13(2), 85-8.
  155. Epperla N, Peterson E, Foy P (2015). An unusual occurrence: a case of venous thromboembolism in pregnancy associated with heterotaxy syndrome. BMC Hematol, 15, 7.
  156. Epperla N, McKiernan F (2015). Iatrogenic Cushing syndrome and adrenal insufficiency during concomitant therapy with ritonavir and fluticasone. Springerplus, 4, 455.
  157. Epperla N, Pathak R (2015). Hypocalcemia Secondary to Zoledronate Therapy in a Patient With Low Vitamin D Level. WMJ, 114(4), 163-6; quiz 167.
  158. Jayarangaiah A, Epperla N (2015). Early recognition is the key to success: pulseless electrical activity (PEA) as a manifestation of heparin-induced anaphylactoid reaction. BMJ Case Rep, 2015.
  159. Epperla N, McKiernan (2015). Iatrogenic Cushing syndrome and adrenal insufficiency during concomitant therapy with ritonavir and fluticasone. SpringerPlus, 4, 455.
  160. Epperla N, Brilliant MH, Vidaillet H (2014). Topical timolol for treatment of epistaxis in hereditary haemorrhagic telangiectasia associated with bradycardia: a look at CYP2D6 metabolising variants. BMJ Case Rep, 2014.
  161. Epperla N, McKiernan FE, Kenney CV (2014). Radiographic findings in Waldenström's macroglobulinemia resembling fibrogenesis imperfecta ossium (FIO): a case report. Skeletal Radiol, 43(3), 381-5.
  162. Epperla N, McKiernan FE (2014). An uncommon cause of acquired osteosclerosis in adults: hepatitis C-associated osteosclerosis. Skeletal Radiol, 43(9), 1313-8.
  163. Epperla N, Landeck J, Sabbagh S (2014). Osmotic demyelination syndrome. WMJ, 113(5), 197-8.
  164. Epperla N, Medina-Flores R, Mazza JJ, Yale SH (2014). Mirtazapine and mefloquine therapy for non-AIDS-related progressive multifocal leukoencephalopathy. WMJ, 113(6), 242-5.
  165. Epperla N, Usoltseva N (2014). Unprovoked deep venous thrombosis in a young adult associated with membranous obstruction of inferior vena cava. BMJ Case Rep, 2014.
  166. Bapani S, Epperla N, Kasirye Y, Mercier R, Garcia-Montilla R (2013). ADAMTS13 deficiency and thrombotic thrombocytopenic purpura associated with trimethoprim-sulfamethoxazole. Clin Med Res, 11(2), 86-90.
  167. Wagner BP, Epperla N, Medina-Flores R (2013). Diagnostic dilemma: late presentation of amelanotic BRAF-negative metastatic malignant melanoma resembling clear cell sarcoma: a case report. Diagn Pathol, 8, 192.
  168. Kasirye Y, Simpson M, Mamillapalli CK, Epperla N, Liang H, Yale SH (2013). Association between blood glucose level and outcomes in patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease. WMJ, 112(6), 244-9; quiz 250.
  169. Kasirye Y, Manne JR, Epperla N, Bapani S, Garcia-Montilla R (2012). Apical hypertrophic cardiomyopathy presenting as recurrent unexplained syncope. Clin Med Res, 10(1), 26-31.
  170. Kasirye Y, Epperla N, Manne JR, Bapani S, Garcia-Montilla RJ (2012). Brain abscesses complicating acute pneumococcal meningitis during etanercept therapy. Clin Med Res, 10(4), 230-5.
  171. Kasirye Y, Danhof RS, Epperla N, Garcia-Montilla RJ (2011). Sweet's syndrome: one disease, multiple faces. Clin Med Res, 9(3-4), 134-6.

Review

  1. Bock AM, Epperla (2025). Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies. Journal of hematology & oncology, 18(1), 68.
  2. Shelley CS, Galiègue-Zouitina S, Andritsos LA, Epperla N, Troussard (2024). The role of the JunD-RhoH axis in the pathogenesis of hairy cell leukemia and its ability to identify existing therapeutics that could be repurposed to treat relapsed or refractory disease. Leukemia & lymphoma, 66(4), 637-655.
  3. Jain N, Mamgain M, Chowdhury SM, Jindal U, Sharma I, Sehgal L, Epperla (2023). Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents. Journal of hematology & oncology, 16(1), 99.
  4. Hanel W, Herrera AF, Epperla N (2022). Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches. [Review]. Exp Hematol Oncol, 11, (1), 108.
  5. Epperla N, Hamadani M (2021). A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine. [Review]. Curr Hematol Malig Rep, 16, (1), 19-24.
  6. Liu Q, Harris N, Epperla N, Andritsos LA (2021). Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant. [Review]. Onco Targets Ther, 14, 1797-1805.
  7. Epperla N, Herrera AF (2021). How I incorporate novel agents into the treatment of classical Hodgkin lymphoma. [Review]. Blood, 138, (7), 520-530.
  8. Hanel W, Epperla N (2021). Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies. [Review]. J Hematol Oncol, 14, (1), 104.
  9. Epperla N, Hamadani M (2021). Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors. [Review]. Hematology Am Soc Hematol Educ Program, 2021, (1), 247-253.
  10. Sircar A, Chowdhury SM, Hart A, Bell WC, Singh S, Sehgal L, Epperla N (2020). Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy. [Review]. Int J Mol Sci, 21, (3).
  11. Hanel W, Epperla N (2020). Emerging therapies in mantle cell lymphoma. [Review]. J Hematol Oncol, 13, (1), 79.
  12. Denlinger NM, Epperla N, William BM (2018). Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. [Review]. Cancer Manag Res, 10, 615-624.
  13. Epperla N, Hamadani M (2017). Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances. [Review]. Hematol Oncol Stem Cell Ther, 10, (4), 277-284.
  14. Epperla N, Mazza JJ, Yale SH (2015). A Review of Clinical Signs Related to Ecchymosis. [Review]. WMJ, 114, (2), 61-5.
  15. Epperla N, Fenske TS, Hari PN, Hamadani M (2015). Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. [Review]. World J Transplant, 5, (3), 81-8.
  16. Epperla N, Fenske TS, Lazarus HM, Hamadani M (2015). Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet? [Review]. Bone Marrow Transplant, 50, (11), 1393-404.
  17. Jayarangaiah A, Sehgal R, Epperla N (2014). Sjögren's syndrome and neuromyelitis optica spectrum disorders (NMOSD)--a case report and review of literature. [Review]. BMC Neurol, 14, 200.
  18. Manne JR, Kasirye Y, Epperla N, Garcia-Montilla RJ (2012). Non-cardiogenic pulmonary edema complicating electroconvulsive therapy: short review of the pathophysiology and diagnostic approach. [Review]. Clin Med Res, 10, (3), 131-6.

Book Chapter

  1. Walter H, Epperla (2025). Hepatosplenic T-cell Lymphoma. 491.
  2. Epperla N, Hanel W, Talpaz (2022). Cytokines, Interferons and Hematopoietic Growth Factors.
  3. Epperla N, Herrera AF, Mei (2022). Hematopoietic cell transplantation in classical Hodgkin lymphoma.
  4. Epperla N, Jayarangaiah A, Fenske T (2017). Hepatosplenic T-cell Lymphoma.
  5. Epperla N, Atallah (2017). Langerhans cell Histiocytosis and Histiocytic Sarcoma.
  6. Epperla N, Fenske T (2017). Mantle Cell Lymphoma.
  7. Epperla N, Hashmi H, Hamadani (2017). Indolent Lymphomas.
  8. Schneidewend R, Epperla N, Friedman (2017). Thrombotic Thrombocytopenia Purpura and the Hemolytic Uremic Syndrome.
  9. Epperla N, Hamadani M, Horowitz M (2017). Establishing a Hematopoietic Stem Cell Transplantation Unit: A Practical Guide.

Editorial

  1. Upshaw JN, Parson SK, Buchsbaum RJ, Schlam I, Ruddy KJ, Durani U, Epperla N, Leong D (2024). Dexrazoxane to Prevent Cardiotoxicity in Adults Treated with Anthracyclines: JACC: CardioOncology Controversies in Cardio-Oncology. JACC. CardioOncology, 6(2), 322-324.
  2. Hanel W, Epperla (2023). Another step toward frontline BTK inhibitor therapy in MCL. Blood advances, 7(23), 7358-7360.
  3. Qian L, De Lima M, Mims AS, Epperla (2022). Editorial: Rising Stars in Hematologic Malignancies 2021. Frontiers in oncology, 12, 858564.

Letter

  1. Umyarova E, Sharp J, Pei C, Pellegrino W, Zhao Q, Denlinger N, Voorhees T, De Lima M, Epperla (2026). Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies. Blood cancer journal, 16(1),
  2. Vaughn JL, Munir M, Cobb A, Rimmalapudi S, Epperla (2026). Evaluation of incidence and outcomes of transformed nodular lymphocyte predominant Hodgkin Lymphoma in the United States: a population-based cohort study. Blood cancer journal, 16(1),
  3. Munir M, Sayed A, Lee DH, Awan F, Ghazi S, Kim J, Addison D, Epperla (2026). Cardiovascular adverse events associated with bispecific antibodies in relapsed or refractory B-cell non-Hodgkin lymphomas. Journal of hematology & oncology, 19(1),
  4. Epperla N, Nastoupil LJ, Feinberg B, Galvin J, Pathak P, Amoloja T, Gentile D, Saverno (2025). Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma. Biomarker research, 13(1), 18.
  5. Chowdhury SM, Bhatta S, Voorhees TJ, Annunzio K, Bond DA, Sawalha Y, Sigmund A, Hanel W, Sehgal L, Alinari L, Baiocchi R, Maddocks K, Christian B, Jones D, Epperla (2025). Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma. Journal of hematology & oncology, 18(1), 4.
  6. Umyarova E, Pei C, Pellegrino W, Zhao Q, Sharma N, Benson D, Cottini F, Bezerra E, Brammer J, Bumma N, Choe H, Denlinger N, Devarakonda S, Khan A, Penza S, Rosko A, Vasu S, Wall S, Alinari L, Baiocchi R, Bond DA, Christian B, Hanel W, Maddocks K, Reneau J, Sawalha Y, Habib A, Sigmund A, Voorhees TJ, de Lima M, Epperla (2025). Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies. Journal of hematology & oncology, 18(1), 30.
  7. Borja-Montes OF, Toro-Pedroza A, Epperla N, Andritsos L (2025). Hairy cell leukaemia and pregnancy: A systematic review and review of literature. British journal of haematology,
  8. Epperla N, Shouse G, Grover NS, Torka P, Annunzio K, Watkins M, Anampa-Guzmán A, Christian B, Thomas C, Barta SK, Geethakumari PR, Karmali R, Bartlett NL, Olszewski A (2025). Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - a US multisite study. Experimental hematology & oncology, 14(1), 73.
  9. Vaughn JL, Ramdhanny A, Munir M, Rimmalapudi S, Epperla (2025). Association of CAR-T approval on outcomes in patients with diffuse large B-cell lymphoma at the population level in the United States. Biomarker research, 13(1), 64.
  10. Munir M, Vaughn JL, Rimmalapudi S, Epperla (2025). Site-specific prognosis and temporal trends in extranodal marginal zone lymphoma patients in the United States. Blood cancer journal, 15(1), 201.
  11. Epperla N, Zhao Q, Moyo T, Watkins MP, Tavakkoli M, Bello C, Torka P, Reddy N, Thomas C, Annunzio K, Christian B, Barta SK, Shouse G, Olszewski AJ, Bartlett N (2024). Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis. [Letter to the Editor]. Blood advances, 8(3), 549-552.
  12. Trabolsi A, Han S, Epperla N, Annunzio K, Baidoun F, Alhaj Moustafa M, Morgenstern-Kaplan D, Doukas P, St-Pierre F, McCall B, Fitzgerald L, Sandoval-Sus J, Dalal S, Reis IM, Chapman-Fredricks JR, Kim SH, Au C, Otto NB, Alhamad K, Ollila T, Karmali R, Shouse G, Lossos IS, Alderuccio J (2024). Outcomes of follicular lymphoma with leukemic phase in the modern era: results from a large multicenter study. Blood neoplasia, 2(1), 100063.
  13. Sayed A, Munir M, Poliner M, Sughra S, Epperla N, Addison (2024). Response to: Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Noguchi et al. Journal for immunotherapy of cancer, 12(4),
  14. Grever M, Andritsos L, Anghelina M, Arons E, Banerji V, Barrientos J, Bhat SA, Blachly J, Broccoli A, Call T, Dearden C, Dietrich S, Else M, Epperla N, Fagarasanu A, Falini B, Forconi F, Gozzetti A, Hampel P, Hermel DJ, Iyengar S, Johnston JB, Juliusson G, Kreitman RJ, Lauria F, Lozanski G, Oakes CC, Parikh SA, Park J, Quest G, Rai K, Ravandi F, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Tiacci E, Troussard X, Wörmann B, Zent CS, Zenz T, Zinzani P (2024). Hairy cell leukemia variant and WHO classification correspondence Re: 5(th) edition WHO classification haematolymphoid tumors: lymphoid neoplasms. Leukemia, 38(7), 1642-1644.
  15. Epperla N, Zhao Q, Anghelina M, Neal J, Blachly JS, Rogers KA, Lozanski G, Oakes CC, Bhat SA, Zent CS, Banerji V, Grever M, Andritsos LA (2023). Impact of sex on outcomes in patients with hairy cell leukemia. An HCL patient data registry analysis. [Letter to the editor]. Am J Hematol, 98(5), E116-E118.
  16. Epperla N, Welkie RL, Torka P, Shouse G, Karmali R, Shea L, Anampa-Guzmán A, Oh TS, Reaves H, Tavakkoli M, Lindsey K, Greenwell IB, Hansinger E, Thomas C, Chowdhury SM, Annunzio K, Christian B, Barta SK, Geethakumari PR, Bartlett NL, Herrera AF, Grover NS, Olszewski AJ (2023). Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study. [Letter to the editor]. J Hematol Oncol, 16(1), 49.
  17. Epperla N, Feng L, Shah NN, Fitzgerald L, Shah H, Stephens DM, Lee CJ, Ollila T, Shouse G, Danilov AV, David KA, Torka P, Hashmi H, Hess B, Barta SK, Romancik JT, Cohen JB, Annunzio K, Kittai AS, Reneau J, Zurko J, Nizamuddin IA, Winter JN, Gordon LI, Ma S, Patel R, Nastoupil L, Ahmed S, Karmali (2023). Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. Journal of hematology & oncology, 16(1), 111.
  18. Vaughn JL, Epperla (2023). Survival of patients with transformed follicular lymphoma in the United States: a multiple cohort study. Biomarker research, 11(1), 84.
  19. Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G (2022). Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study. [Letter to the editor]. J Hematol Oncol, 15(1), 96.
  20. Vaughn JL, Gundepalli SG, Epperla N (2022). Racial differences in the survival of mantle cell lymphoma patients in the United States. [Letter to the editor]. Hematol Oncol, 40(3), 479-481.
  21. Vaughn JL, Pinheiro LC, Olszewski A, Epperla N (2021). Survival of patients with marginal zone lymphoma in the United States: A population-based cohort study (2000 to 2017). [Letter to the editor]. Am J Hematol, 96(4), E123-E126.
  22. Vaughn JL, Zhao Q, Epperla N, Puto M, Roddy J, Elder P, Blum W, Klisovic R, Jaglowski S, Penza S, William B, Andritsos L, Brammer JE, Hofmeister C, Efebera Y, Benson D, Devine S, Cataland S, Vasu S (2019). Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease? [Letter to the editor]. Bone Marrow Transplant, 54(6), 913-916.
  23. Epperla N, Hamadani M, Fenske TS, Costa LJ (2018). Incidence and survival trends in mantle cell lymphoma. [Letter to the editor]. Br J Haematol, 181(5), 703-706.
  24. Epperla N, Kleman A, Karafin M, Foy P (2018). Re-treatment versus extended treatment strategy of systemic bevacizumab in hereditary hemorrhagic telangiectasia: which is better? [Letter to the editor]. Ann Hematol, 97(9), 1727-1729.
  25. Epperla N, Pasquini M, Pierce K, Drobyski WR, Rizzo JD, Horowitz MM, Saber W, Zellner K, Ramirez S, Bartz K, Raj RV, Hari PN, Hamadani M (2017). Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft. [Letter to the editor]. Bone Marrow Transplant, 52(1), 147-150.
  26. Jerkins JH, Hamadani M, Zook F, Epperla N, Shaw BE, Saber W, Rizzo JD, Pasquini M, Chhabra S, Drobyski WR, Hari PN, Shah NN (2017). Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. [Letter to the editor]. Am J Hematol, 92(10), E610-E611.
  27. Epperla N, Kapke JT, Karafin M, Friedman KD, Foy P (2016). Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding. [Letter to the editor]. Am J Hematol, 91(6), E313-4.
  28. Hebbring SJ, Slager SL, Epperla N, Mazza JJ, Ye Z, Zhou Z, Achenbach SJ, Vasco DA, Call TG, Rabe KG, Kay NE, Caporaso NE, Lanasa MC, Camp NJ, Strom SS, Goldin LR, Cerhan JR, Brilliant MH, Schrodi SJ (2013). Genetic evidence of PTPN22 effects on chronic lymphocytic leukemia. [Letter to the editor]. Blood, 121(1), 237-8.

Abstract

  1. Kim K, Sun X, Voorhees T, Youssef Y, Epperla N, De Castro M, Ow K, Santiago M, Varghese J, Ayers A, Hawkins M, Leautaud V, Ramdial J, Kebriaei P, Shpall E, Liu H, Jain M, Chavez J, Locke F, Sattva N, Ahmed S, Paolo (2025). 456 | Identification Of An Optimal Absolute Lymphocyte Count Before Leukapheresis In Large B'Cell Lymphoma Patients Treated With Cart. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025. 43(S3),
  2. Bock AM, Baron K, Wagner C, Fitzgerald L, Ermann D, Hu B, Shah H, Zak J, Epperla (2025). 504 | Impact Of The Neutrophil/Lymphocyte Ratio On Outcomes Following Bispecific Antibody Therapy In Relapsed/Refractory Lymphoma Patients. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025. 43(S3),
  3. Baron K., Wagner C, Fitzgerald LA, Ermann DA, Hu B, Epperla N, Shah HA, Bock (2025). 620 | A Standardized Process For A Rapid Dose Escalation Of Epcoritamab For Patients With Lymphoid Malignancies In The United States. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025. 43(S3),
  4. Bock AM, Feng L, Ayers A,Chauhan A, Thiruvengadam S, Jallouk A, D'Angelo C, Sawalha Y, Godbole S, Merryman R, Bhaskar S, Baron K, Lunning M, Herrera A, Crombie JL, Epperla N, Ahmed (2025). 667 | Real'World Safety And Efficacy Of Epcoritamab For Patients With Relapsed/Refractory Large B'Cell Lymphomas. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025. 43(S3),
  5. Shouse G, Ahmed S, Chen L, Salles G, Bock AM, Lunning MA, Godbole S, Sawalha Y, Ayers AA, Thiruvengadam S, Goth C, Flowers CR, Chauhan A, Epperla N, Herrera A, Danilov AV, Falchi (2025). 671 | Glofitamab For The Treatment Of Relapsed/Refractory Diffuse Large B Cell Lymphoma, A Real'World Evidence Study From The Cubic Consortium. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025. 43(S3),
  6. Thiruvengadam SK, Chen L, Ahmed S, Bock A, Epperla N, Godbole S, Sawalha Y, Jallouk A, Bhaskar S, Falchi L, Salles G, Lunning M, Crombie J, Merryman R, Ayers AA, Goth C, Shouse G, Flowers C, Danilov A, Herrera AF, Chauhan (2025). 161 | Outcomes Of Glofitamab And Epcoritamab In R/R Dlbcl Elderly Patients: A Real'World Evidence Study From The Cubic Consortium. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025. 43(S3),
  7. Baggio D, Han S, Ghione P, Okcu I, Okosun J, Kamdar M, Kuhnl A, Grover N, Cherng H, Olszewski A, Ramakrishnan Geethakumari P, Smith J, Prica A, Khwaja J, Osborne W, Koff J, El-Sharkawi D, Wagner-Johnston N, Munoz J, Desai A, Epperla N, Baidoun F, Moyo T, Narkhede M, Barrett A, Linton K, Wallace D, Elmusharaf N, Sandoval-Sus J, Danilov A, Rhodes J, Santarsieri A, Karim F, Calabrese De Feo J, Tavarozzi R, Nizamuddin I, Dong N, Saha A, Hann W, Wang Y, Treitman R, Maraj A, Tolu S, Ollila T, Abeyakoon C, Calvert V, Ayers A, Hilali A, Trutzer I, Monick S, Sharp J, Tun H, Ghosh N, Collins GP, Deshani V, Can J, Kallam A, Kahl B, Chavez J, Cwynarski K, Alderuccio J (2025). 339 | Outcomes In An International Multicentre Study Of 600 Patients With CNS Relapse Of Large B Cell Lymphoma: Compartment Of Relapse Is Prognostic. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025. 43(S3),
  8. Stephan P, Chohan KL, Redd RA, Ahmed S, Flowers CR, Chauhan A, Ayers AA, Shouse G, Thiruvengadam SK, Herrera AF, Bock AM, Epperla N, Buckley SM, Hu B, Lunning MA, Salles G, Falchi L, Sawalha Y, Godbole S, Jallouk AP, Bhaskar ST, Armand P, Merryman RW, Crombie JL, Danilov A (2025). 243 | Real'World Outcomes Of Cd20xcd3 Bispecific Antibody Therapy In Adult Patients With Relapsed/Refractory Transformed Indolent Lymphoma. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025. 43(S3),
  9. Jallouk A, Feng L, Ayers A, Chauhan A, Thiruvengadam S, Bock A, Bhaskar S, Epperla N, Herrera A, Ahmed (2025). 566 | Real-World Outcomes Of Mosunetuzumab Use From The Cubic Consortium. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025. 43(S3),
  10. Cortese MJ, Herr MM, Nair NM, Romancik JT, Stephens DM, Bhansali R, Moyo TK, Kenkre VP, Ollila T, Hess BT, Fitzgerald L, Shouse G, Matasar M, Davis J, Jesme C, Pelcovits A, Moreira J, Lin AY, Ma S, Winter J, Danilov AV, Shah NN, Barta SK, Cohen JB, Gordon LI, Epperla N, Grover N, Karmali (2025). 303 | Clinical Outcomes of Transformed Marginal Zone Lymphoma and Richter Transformation with CAR T-Cell Therapy: A US Multicenter Real-World Analysis. Abstracts from the 2025 Tandem Meetings of ASTCT and CIBMTR, February 2025, Honolulu, Hawaii. 31(2 (Supplement)), S224-S225.
  11. Epperla N, Adedokun B, Hashmi H, Shadman M, Winter AM, Herrera AF, Hamadani M, Jacobson C, Ahmed N, Perez W, Feng Z, Hu K, Du B, Kim J, Best T, Baer A, Pradhan A, Pasquini MC, Ahmed (2025). 7024| Real-world outcomes of axicabtagene ciloleucel (axi-cel) for the treatment of relapsed/refractory (R/R) secondary central nervous system lymphoma (SCNSL). 2025 ASCO Annual Meeting, Chicago, IL. 43(16_Supplement),
  12. Oh TS, Herr MM, Grover N, Romancik JT, Epperla N, Cortese MJ, Bhansali R, Moyo TK, Kenkre VP, Nair NM, Ollila T, Hess BT, Fitzgerald L, Shouse G, Matasar M, Davis J, Jesme C, A Pelcovits, J Moreira J, Lin A, Ma S, Winter J, Danilov AV, Shah NN, Barta SK, Cohen JB, Gordon LI, Stephens DM, Karmali (2025). 59 | A Comparison of Survival in Younger Vs Older Patients Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) for Aggressive B-Cell Lymphoma. Abstracts from the 2025 Tandem Meetings of ASTCT and CIBMTR, February 2025, Honolulu, Hawaii. 31(2 (Supplement)), S46-S47.
  13. Shaaban A, Habib A, Ghazi S, Sharma S, Salem A, Ferdousi M, Ruz P, Epperla N, Addison (2025). 4369783| Clinical Safety Outcomes of ICI Rechallenge following ICI-myocarditis and other Cardiotoxicities. 152(3),
  14. Scheffer Cliff E, Pelaez G, Wan F, Iyengar V, Zhou J, Chung K, Abdel-Razeq N, Allen J, Major A, Sharp J, Epperla N, Gould P, Cherng H, Houshyar S, Wallace D, Lynch R, Kallam A, Mei M, Merryman R, Fleyshman M, Rhodes J, Kidwell A, Fenske T, Malakhov N, Mulvey E, Watkins M, Moustafa M, Halal T, Nowakowski G, Wang Y, Torka P, Russler-Germain (2025). Cell-Of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B Cell Lymphoma.
  15. Altomare N, Herr M, Nair N, Stephens D, Epperla N, Cortese M, Bhansali R, Moyo T, Kenkre V, Ollila T, Hess B, Fitzgerald L, Shouse G, Davis J, Jesme C, Pelcovits A, Moreira J, Lin A, Ma S, Winter J, Danilov A, Barta S, Cohen J, Gordon L, Romancik J, Grover N, Karmali (2025). 545| Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART. 31(2, Supplement), S387-S388.
  16. Cortese MJ, Herr MM, Nair N, Romancik J, Grover N, Bhansali RS, Thomas C, Moyo TK, Kenkre VP, Ollila T, Hess B, Fitzgerald L, Shouse G, Matasar M, Annunzio K, Davis JA, Jesme C, Pelcovits A, Melody M, Moreira J, Lin AY, Ma S, Winter JN, Niu A, Danilov AV, Shah NN, Stephens DM, Cohen JB, Gordon LI, Barta SK, Epperla N, Karmali (2024). Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis. American Society of Hematology (ASH Publication). (2024) 144 (Supplement 1)(525),
  17. Melody M, Grover N, Franco S, Romancik JT, Cortese MJ, Moyo TK, Bhansali RS, Ollila T, Kenkre VP, Fitzgerald L, Hess B, Matasar M, Shouse G, Annunzio K, Herr MM, Davis JA, Jesme C, Pelcovits A, Moreira J, Ma S, Winter JN, Yuh Lin A, Danilov A, Roy I, Barta SK, Gordon LI, Stephens DM, Cohen JB, Epperla N, Karmali (2024). Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma. American Society of Hematology (ASH Publication). (2024) 144 (Supplement 1)(473),
  18. Ellsworth BL, Melody M, Epperla N, Grover N, Romancik JT, Cortese MJ, Bhansali RS, Moyo TK, Kenkre VP, Ollila T, Hess B, Fitzgerald L, Shouse G, Matasar M, Annunzio K, Herr MM, Davis JA, Jesme C, Pelcovits A, Moreira J, Lin AY, Ma S, Winter JN, Danilov AV, Shah NN, Barta SK, Cohen JB, Gordon LI, Stephens DM, Karmali (2024). Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy. American Society of Hematology (ASH Publication). (2024) 144 (Supplement 1)(612),
  19. Kenkre VP, Lin Y, Epperla N, Rajguru SA, Chang JE, Pophali PA, Harris EI, Fletcher CD, Matasar M, Eltoukhy H, Bond DA, Sawalha Y, Christian B, Voorhees T, Endres M, Howard M, Bhavsar D, Fleming M, Carter JS, Evens A (2024). 623| A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study. 144(Supplement 1), 4415.
  20. Sharp J, Strati P, Bhatta S, Huang J, Thomas C, Reff D, Gorzewski A, Reinert C, Teferra A, Pelcovits A, Ollila T, Maakaron J, Kamdar M, Fitzgerald L, Karmali R, Grover N, Barta S, Voorhees T, Shadman M, Ahmed S, Epperla (2024). 906| Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers. 144(Supplement 1),
  21. Bond D, Huang Y, Reneau J, Sawalka Y, Brammer J, Voorhees T, Epperla N, Sigmund A, Alinari L, Hanel W, Gilmore A, Fleming M, Stamper K, Baiocchi R, Christian B, Maddocks (2024). Nivolumab in Combination with Dose Adjusted (DA) R-EPOCH for First-Line Treatment of Large B-Cell Lymphoma: Results from a Phase II Trial. 144(Supplement 1),
  22. Saverno K, Nastoupil L. Feinberg B, Galvin J, Pathak P, Amoloja T, Gentile D, Asgarisabet P, Epperla (2024). Real-World Effectiveness of Tafasitamab (Tafa) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States. 144(Supplement 1),
  23. Sharp J, Bhatta S, Takacs N, Tong K, Youssef Y, Bond D, Sawalha Y, Sigmund A, Sehgal L, Alinari L, Baiocchi R, Maddocks K, Christian B, Voorhees T, Epperla (2024). Impact of Baseline Osseous Involvement on Outcomes in Patients with Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom's Macroglobulinemia (WM). 144(Supplement 1),
  24. Ramdhanny A, Vaughn J, Epperla (2024). Impact of Chimeric Antigen Receptor T-Cell Therapy on Survival in Patients with Diffuse Large B-Cell Lymphoma at the Population Level in the United States. 144(Supplement 1),
  25. Wang J, Zhou J, Wang Y, Munoz J, Shim K, Moustafa MA, Baidoun F, Annunzio K, Epperla N, McClane M, Karimi Y, Luu B, Spurgeon S, Chang C, Wan Z, Gathers D, King E, Watkins M, Bartlett N, Ryan C, Gerhard G, Armand P, LaCasce A, Vaddaraju V, Wallace D, Kenkre V, Junge C, Grover N, Florindez J, Karmali R, Stanisic A, Zhang C, Venugopal P, Ying G, Gribbin C, Ruan J, Shakula N, Smith S, Zelikson V, Williams M, Barta S, Elghawy O, Schade J, Navalekar R, Matasar M, Evens A, Danilov A, Fenske (2024). Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutates Mantle Cell Lymphoma. 144(Supplement 1),
  26. Vaughn J, Epperla (2024). Trends in Incidence and Survival of Patients with Primary Effusion Lymphoma in the United States. 144(Supplement 1),
  27. St-Pierre F, Bhatta S, Doukas P, Jenkin M, Annunzio K, Rojek A, Tiger YK, McCall B, Alhamad K, Hansen A, Alderuccio JP, Adewale O, Patel K, Trabolsi A, Lossos I, Fitzgerald L, Ollila T, Matasar M, Kline J, Karmali R, Epperla (2024). Outcomes of Chimeric Antigen Receptor (CAR) T-Cell therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis. 144(Supplement 1),
  28. Epperla N, Grover N, Torka P, Karmali R, Annunzio K, Watkins M, Anampa-Guzman A, Reves H, Tavakkoli M, Christian B, Thomas C, Barta S, Ramakrishnan Geethakumari P, Shouse G, Bartlett N, Olszewski (2024). Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study. 144(Supplement 1),
  29. Wang Y, Singh S, Odier A, La Ferlita A, Chan W, Berger M, Sreekanth S, Epperla N, Mathusamy N, Baiocchi R, Alinari L, Gupta M, Sehgal (2024). Tumor Microenvironment-Induced Interleukin-6 Regulates Proliferation and Survival in Patients with Mantle Cell Lymphoma (MCL) By Activating FGFR1 Signaling. 144(Supplement 1), 4371.
  30. Tariq MJ, Attwood K, Anampa-Guzman A, Hamid S, Niu A, Kaldas D, Thapa S, Leng J, Youssef Y, Carroll K, Treitman R, Rafae A, Singhal S, Nakhoda S, Al Hadidi S, Bair S, Voorhees T, Epperla N, Caimi P, Grajales-Cruz A, Hernandez-Ilizaliturri F, Cortese (2024). Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis. 144(Supplement 1), 4392.
  31. J Sharp, Q Zhao, T Voorhees, D BonSawalha Y, Reneau J, SIgmund A, Hanel W, Sehgal L, Alinari L, Baiocchi R, Brammer J, Maddocks K, Christian B, Bezzera E, Denlinger N, Vasu S, de Lima M, Prosek J, Epperla (2024). Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy Is Associated with Inferior Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma. 144(Supplement 1), 3747.
  32. Singh S, La Ferlita A, Jain N, Berger M, Sreekanth S, Distefano R, Gupta M, Muthusamy N, Baiocchi R, Alinari L, Epperla N, Sehgal (2024). Transcriptomic Analysis in Mantle Cell Lymphoma Patients Identified MALAT1 Long-Non-Coding RNA to Regulate Cell Cycle Progression By Modulating EZH2/p57/Sox11 Axis. 144(Supplement 1), 4350.
  33. Montes OB, Jawadi A, Varatharaj S, Herring H, Gil TE, Epperla N, Andritsos (2024). Evaluation of Measurable Residual Disease Assessment Dynamics in Hairy Cell Leukemia Clinical Trials from 1980 to 2020. 144(Supplement 1), 7787.
  34. Lu X, Bokun A, Yang C, Wang Y, Chen W, Wang J, Epperla (2024). Estimating and Projecting the Number of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) By Treatment Lines in the United States. 144(Supplement 1), 7618.
  35. Alderuccio JP, Khwaja J, Han S, Ghione P, Nizamuddin I, Saha A, Dong N, Wang Y, Cherng HJ, Tolu S, Wagner-Johnston N, Olszewski A, Grover N, Koff J, Desai A, Ramakrishnan Geethakumari P, Moyo T, Sandoval-Sus J, Epperla N, Wallace D, Kamdar M, Danilov A, Tun H, Munoz J, Narkhede M, Rhodes J, Prica A, Kuhnl A, Maraj A, Okosun J, Smith J, Osborne W, Calvert V, el-Sharkawi D, Hilali A, Collins G, Linton K, Elmusharaf N, Santarsieri S, Karim F, Ollila T, Monick S, Trutzer IM, Ghosh N, Can J, Ayers A, De Feo JC, Sharp J, Treitman R, Kallam A, Okcu I, Deshani V, Baidoun F, Abeyakoon C, Hann W, Barrett A, Kahl B, Chavez J, Cwynarski (2024). Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort. 144(Supplement 1), 571.
  36. Scheffer Cliff E, Pelaez G, Wan F, Iyengar V, Zhou J, Chung K, Abdel-Razeq N, Major A, Allen J, Sharp J, Epperla N, Gould P, Cherng HJ, Houshyar S, Wallace D, Lynch R, Kallam A, Mei M, Merryman R, Fleyshman M, Rhodes J, Kidwell A, Fenske T, Mulvey E, Watkins M, Moustafa MA, Hilal T, Nowakowski G, Wang Y, Torka P, Russler-Germain (2024). The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin. 144(Supplement 1), 652.
  37. Vasu S, Bezzera E, Denlinger N, Szuminski N, Schneider D, Dash P, Wirthlin L, Epperla N, Sawalha Y, Woyach J, Rodgers K, Bhat S, Behbehani G, Larking K, Kittai A, Chan W, Krull A, Nishat S, O'Donnell L, Alinari L, de Lima (2024). Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies. 144(Supplement 1), 2078.
  38. Nizamuddin I, Epperla N, Malacek MK, Kahl B, Wan F, Fischer A, Moreno C, King E, Krivenko A, Bartlett N, Mehta-Shah (2024). Phase I Results of Acalabrutinib in Combination with Durvalumab in Primary Central Nervous System Lymphoma: Safety, Efficacy, and Central Nervous System Penetration. 144(Supplement 1), 985.
  39. Alencar A, Bobek O, Mehta-Shah N, Epperla N, Lu-Emerson C, Rutherford S, Olszewski A, Ollila T, Singer S, Dockter T, Geyer S, Rosenstein L, De La Fuente M, Hsi E, Dinner S, Rubenstein J, Bartlett N, Leonard (2024). Trial in Progress - Alliance A051901 - Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL). 144(Supplement 1), 4502.4.
  40. Neelapu S, Chavez J, Sehgal A. Epperla N, Ulrickson M, Bachy E, Munshi P, Casulo C, Malone D, de Vos S, Reshef R, Leslie L, Oluwole O, Yakoub-Agha I, Khanal R, Rosenblatt J, Wulff J, Shen R, Zhang W, Poddar S, Miao H, Nikolajeva O, Jacobson (2024). 5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. 144(Supplement 1), 864.
  41. Epperla N, Lucero M, Bailey T, Mirams L, Cheung J, Amet M, Milligan G, Keir C, Chen (2024). ABCL-370 Real-World Clinical Effectiveness of Loncastuximab Tesirine Monotherapy for the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma Following Chimeric Antigen T-Cell Therapy in the US. 24(Supplement 1), S476.
  42. Epperla N, Nastoupil L, Feinberg B, Galvin J, Pathak P, Amoloja T, Gentile D, Saverno (2024). ABCL-406 Real-World Sequential Use of CD19-Directed Therapies for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab Preceding Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. 24(Supplement 1), S477.
  43. Epperla N, Nastoupil LJ, Savill KMZ, Zimmerman K, Feinberg B, Galvin J, Pathak P, Amoloja T, Vukcevic M, Saverno (2024). ABCL-206: Real-World Use of Tafasitamab for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the United States by Age Group (>70 Years and ≤70 Years). 46(Supplement 4), S213.
  44. Nizamuddin I, Kahl B, Bartlett N, Epperla N, Mehta-Shah (2024). Trial in Progress: Phase 1 Study with Dose Expansion of Acalabrutinib and Durvalumab (MEDI 4736) in Primary Central Nervous System Lymphoma. 24(Supplement 1), S219.
  45. Sverno K, Zimmerman K, Feinberg B, Galvin J, Pathak P, Amoloja T, Epperla N, Nastoupil (2024). ABCL-207: Real-World Use of Tafasitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States by Primary Refractory Status. 24(Supplement 1), S213.
  46. Nizamuddin I, Kahl B, Bartlett N, Epperla N, Mehta-Shah (2024). ABCL-607: Trial in Progress: Phase 1 Study with Dose Expansion of Acalabrutinib and Durvalumab (MEDI 4736) in Primary Central Nervous System Lymphoma. 24(Supplement 1), S484-S486.
  47. Habib A, Welkie R, Butman J, Silberman P, Forero J, Sawalha Y, Christian B, Maddocks K, Epperla N, Jaglowski S, Bond D, Choe H, Brammer J, Kittai A, Bezerra E, Voorhees T, Vasu S, Wall S, De Lima M, Denlinger (2024). Secondary Myeloid Malignancy after CAR T cell therapy for non-Hodgkin lymphoma (NHL). 42(Number 16 Supplemental), 7033.
  48. Durisek G, Voorhees T, Denlinger N, Epperla N, Sigmund A, Sanches-Petitto G, Sawalha Y, Bond D, Choe H, Wall S, Brammer J, Alinari L, Christian B, Cataland S, Jagloqski S, Maddocks K, De Lima M, Vasu S, Bezerra (2024). Association between post-CART terminal complement complex (TCC) levels and clinically significant immune effector cell-associated neurotoxicity syndrome (ICANS). 42(Number 16 Supplemental), 7036.
  49. McNally G, Xu M, Voorhees T, Baiocchi R, Bond D, Epperla N, Maddocks K, Sawhala Y, Ramaswamy B, Lustberg (2024). Neurofilament light chains: A biomarker for vincristine-related neuropathy. 42(Number 16 Supplemental), 12114.
  50. Singh S, Sircar A, Odier A, Epperla N, Muthusamy N, Parekh S, Sehgal (2024). Abstract 3165: Targeting angiogenesis for improved survival in mantle cell lymphoma. 84(Supplement 6), 3165.
  51. LaFerlita A, Singh S, Sircar A, Baiocchi R, Muthusamy N, Alinari L, Epperla N, Sehgal (2024). Abstract 2997: Identification of novel long non-coding RNAs in mantle cell lymphoma patients. 84(Supplement 6), 2997.
  52. Hashimi H, Epperla N, Ahn K, Allbee-Johnson M, Mercadal S, Lee C, Shadman M, Sauter C, Hamadani M, Herrera A, Ahmed (2024). Abstract 48: Outcomes of Large B-Cell Lymphoma (LBCL) Patients with Secondary Central Nervous System Involvement Following Chimeric Antigen Receptor T-Cell Therapy: A CIBMTR Analysis. 30(2 Supplement), S42.
  53. Voorhees T, Huang Y, Denlinger N, Epperla N, Brammer J, Sawalha Y, Bond D, Bezerra E, Needham T, Reneau J, Sigmund A, Hanel W, Alinari L, Christian B, Baiocchi R, Maddocks K, Jaglowski S, Vasu S, de Lima M, Caimi (2024). Abstract 486: Siltuximab Prophylaxis Prior to Standard of Care CD19 Directed Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: Interim Results from a Phase 1 Clinical Trial. 30(2 Supplement), S355-S356.
  54. Bajwa A, Zhao Q, Geer M, Mian A, Lin C, Frame D, Westholder J, Tossey J, Ghosh M, Galal A, Ahmed N, Maakaron J, Denlinger N, de Lima M, Epperla N, Caimi P, Voorhees (2024). Abstract 261: Efficacy of Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Toxicities - a Multicenter Retrospective Analysis. 30(2 Supplement), S201-S202.
  55. Abedin S, Chhabra S, Epperla N, Longo W, Pasquini M, Peterson K, Fenske T, Runaas L, Shah N, Hamadani (2024). Abstract 217: Reduced Intensity Conditioning (RIC) Transplant with Very Low Dose Evomela Is Safe and Effective in Patients with Hematologic Malignancies Undergoing Haploidentical Donor Transplant. 30(2 Supplement), S167-S168.
  56. Epperla N, Lucero M, Bailey T, Mirams L, Cheung J, Amet M, Milligan G, Chen (2024). Abstract 482: Real-World Clinical Effectiveness of Loncastuzimab Tesirine Monotherapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Following Chimeric Antigen T Cell Therapy in the US. 30(2 Supplement), S353.
  57. Sayed A, Munir M, Ghazi S, Ferdousi M, Krishan S, Shaaban A, Habib A, Kola O, Kehinde, Ruz P, Khan S, Sharma S, Meara A, Mahmood S, Feldman S, Yang E, Kim J, Epperla N, Addison (2024). Cardiovascular toxicities associated with bispecific T-cell engager therapy. 12(2),
  58. Sawalha Y, Welkie R, Krivenko A, Hess B, Sigmund A, Voorhees T, Hanel W, Bond D, Reneau J, Epperla N, Alinari L, Brammer J, Christian B, Baiocchi R, Maddocks (2023). Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Predinisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial. . 142(Supplement 1), 6226.
  59. Lehanka A, Kebede A, Amirmokhtari N, Stanek J, Epperla N, Christian B, Baiocchi R, Voorhees T, Maddocks K, Sawalha Y, Reneau J, Brammer J, Sigmund A, Willen F, Yeager N, Audino A, Bond (2023). Differences in Observed Toxicities for Adolescent and Young Adult Patients with Aggressive Mature B-Cell Lymphomas Treated with Adult Versus Pediatric Cancer Center - a Comparative Cohort Study. 142(Supplement 1), 3116.
  60. Epperla N, Annunzio K, Shouse G, Grover N, Torka P, Watkins M, Anampa-Guzman A, Oh T, Reves H, Tavakkoli M, Hansinger E, Christian B, Thomas C, Barta S, Ramakrishnan Geethakumari P, Karmali R, Bartlett N, Olszewski (2023). Impact of Maintenance Rituximab Following First-Line Systemic Therapy on Outcomes in Patients with Marginal Zone Lymphoma: Real-World Evidence from 10 US Centers. 142(Supplement 1), 5147.
  61. Voorhees T, Grover N, McLaughlin E, Florindez J, Mayo T, Reves H, Sumransub N, Deshpande S, Rose A, Duarte C, Faisal MS, Hamid S, Subbiah S, Ayyappan S, Shea L, Cortese M, Patel K, Major A, Saeed H, Svoboda J, Desai S, Ramakrishnan Geethakumari P, Torka P, Epperla (2023). Allogeneic Stem Cell Transplant and CD30 Directed CART Cell Therapies Are Associated with Improved Survival in Classical Hodgkin Lymphoma Refractory or Intolerant Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Ananlysis from 14 U.S. Academic Centers. . 142(Supplement 1), 900.
  62. Epperla N, Nastoupil L, Zimmerman Savill K, Feinberg B, Galvin J, Pathak P, Gordon S, Llorente T, Saverno (2023). Real-World Use of Tafasitamab (tafa) for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Among Racial and Ethnic Minorities in the United States. 142(Supplement 1), 2415.
  63. Epperla N, Annunzio K, Shouse G, Grover N, Torka P, Watkins M, Anampa-Guzman A, Oh T, Reves H, Tavakkoli M, Hansinger E, Christian B, Thomas C, Barta S, Ramakrishnan Geethakumari P, Karmali R, Bartlett N, Olszewsk (2023). Impact of Diagnosis to Treatment Interval on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - a US Multisite Study. 142(Supplement 1), 5159.
  64. Saverno K, Zimmerman Savill K, Feinberg B, Galvin J, Pathak P, Gordon S, Amoloja T, Llorente M, Epperla N, Nastoupil (2023). Abstract 265: Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting. 142(Supplement 1), 265.
  65. Neelapu S, Chavez J, Sehgal A, Epperla N, Ulrickson M, Bachy E, Munshi P, Casulo C, Maloney D, de Vos S, Reshef R, Leslie L, Oluwole O, Yakoub-Agha I, Khanal R, Rosenblatt J, Peng W, Lui C, Wulff J, Shen R, Poddar S, Lee A, Miao H, Nikolajeva O, Jacobson (2023). Abstract 4868: Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial. 142, 4868.
  66. Trabolsi A, Epperla N, Annunzio K, Morgenstern Kaplan D, Doukas P, St-Pierre F, McCall B, Fitzgerald L, Han S, Reis I, Chapman-Fredericks J, Alhamad K, Ollila T, Karmali R, Lossos I, Alderuccio (2023). Abstract 3770: A Multicenter Study Analyzing Survival and Prognostic Factors in Patients with Leukemic Phase Follicular Lymphoma. 142(Supplement 1), 3770.
  67. Epperla N, Switchenko J, Geyer S, Bachanova V, Barta S, Danilov A, Grover N, Karmali R, Hill B, Ghosh N, Fenske T, Martin P, Kahl B, Flowers C, Link B, Hsi E, Maddocks K, Blum K, Habermann T, Maurer M, Kaplan L, Bartlett N, Leonard J, Cohen (2023). Abstract 380: Ki-67 Expression of 50% is the Optimal Cut-Off to Predict Survival Outcomes in Mantle Cell Lymphoma (MCL): A Pooled Analysis from CALGB 50403 (Alliance) and MCL Real-World Study Cohort. 142(Supplement 1), 380.
  68. Epperla N, Zhao Q, Anghelina M, Neal J, Blachly JS, Rogers KA, Lozanski G, Oakes C, Bhat S, Banerji V, Zent C, Grever MR, and Andritsos L (2022). Impact of sex on outcomes in patients with hairy cell leukemia (HCL): An HCL patient data registry analysis. ASCO Annual Meeting; June 2022. Chicago, IL. 40(16_Supplement), 7577-7577.
  69. David KA, Sundaram S, Kim S, Vaca R, Lin Y, Singer S, Malecek M, Carter J, Zayac A, Kim MS, Reddy N, Habib A, Strouse C, Graber J, Bachanova V, Tsang M, Major A, Bond D, Agrawal P, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Glantz M, Goldlust S, Matnani R, Kumar P, Ollila TA, Cai J, Spurgeon S, Sieg A, Cleveland J, Epperla N, Karmali R, Naik S, Martin P, Smith SM, Rubenstein J, Kahl B, Evens AM (2021). Older patients with primary CNS lymphoma: Real world outcomes of post-induction therapy in the modern era. International Conference on Malignant Lymphoma (ICML); June 2021. (virtual). 39(2),
  70. Epperla N, Badar T, Szabo A, Vaughn J, Borson S, Saini NY, Patel RD, Shah NN, Hamadani M, Ahmed S, Cashen A, Fenske (2019). Post-relapse survival in Diffuse Large B-cell Lymphoma patients after experiencing therapy failure following autologous hematopoietic cell transplantation. 25(3), S22.
  71. Romancki J, Switchenko J, Shanmugasundaram K, Goyal S, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson J, Barta SK, Gordon M, Danilov A, Grover NS, Mathews M, Burkhart M, Karmali R, Swalha Y, Hill BT, Ghosh N, Park SI, Epperla N, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Kahl BS, Martin P, Guo J, Flowers CR, Cohen (2019). The Impact of Pre-Diagnosis Tobacco use in Mantle Cell Lymphoma. 134(Suppll 1), 5891.
  72. Maddocks K, Awan F, Huang Y, Ayyappan S, Baiocchi R, Epperla N, Jaglowski S, William B, Blum K, Christian (2018). Preliminary results of a phase I study of Obinutuzumab, venetoclax and lenalidomide in relapsed and refractory B-cell non-Hodgkin lymphoma. 132(Suppl 1), 4185.

Other

  1. Anghelina M, Naughton MJ, Zhao Q, Ruppert AS, Neal J, Rogers KA, Blachly JS, Lozanski G, Bhat SA, Kraut E, Epperla N, Mathur P, Zent CS, Banerji V, Dearden C, Hutchinson T, Grever M, Andritsos L (2022). Corrigendum to "Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemia" [Leuk. Res. 120 (2022) 106919]. Leukemia research, 121, 106943.

Video/Film/CD/Web/Podcast

  1. Epperla (2025). Lymphoma and CAR T–Related Renal Injury: Assessing the Risks.
  2. Epperla (2024). MCL: Dual Therapy ‘Promising’ in patients with TP53 mutations.
  3. Epperla (2024). Dr. Epperla on spotlight on follicular lymphoma therapies: Highlights from ASH 2024.
  4. Epperla (2024). Dr. Epperla on new and emerging treatment options for follicular lymphoma.
  5. Epperla (2023). Dr. Epperla on assessing the optimal Ki-67 cut-off for outcomes prediction among patients with newly diagnosed mantle cell lymphoma: Pooled Analysis from the CALGB50403 (Alliance) and MCL Real-World study cohort.
  6. Epperla (2023). Dr. Epperla on analyzing outcomes of tafasitamab for the treatment of R/R DLBCL among racial and ethnic minorities: Real-world data results.
  7. Epperla (2023). Diagnosis to treatment interval: A crucial prognostic factor in newly diagnosed mantle cell lymphoma .
  8. Epperla (2023). Dr. Epperla and Dr. Andritsos on gender and patients outcomes in HCL using HCL patient data registry.
  9. Epperla (2022). Dr. Epperla on BTK inhibitors in R/R MZL; MedEd On The Go - BTKs in B-Cell Lymphomas: Current Challenges and Emerging Solutions.
  10. Epperla (2022). Dr. Epperla on the prognostic outlook for patients with doube-hit lymphoma.
  11. Epperla (2021). Epperla Elucidates on Excitement With Tafasitamab and Selinexor in DLBCL. Dr. Epperla expands on findings from the L-MIND trial in DLBCL, as well as the significance of selinexor and other options in the pipeline. .
  12. Epperla (2021). Dr. Epperla on the implications of a potential FDA approval for the combination of ublituximab and umbralisib for patients with chronic lymphocytic leukemia .
  13. Epperla (2021). Dr. Epperla on the efficacy of brexucabtagene autoleucel in patients with mantle cell lymphoma.
  14. Epperla (2021). Dr. Epperla on future research efforts in MCL .
  15. Epperla (2021). Dr. Epperla expands on findings from the L-MIND trial in DLBCL, as well as the significance of selinexor and other options in the pipeline.
  16. Epperla (2017). Dr. Epperla on FDA approval of frontline Obinutuzumab in Follicular Lymphoma .
  17. Epperla (2017). Dr. Epperla on CAR T-cell therapy in MCL.
  18. Epperla (2017). Adding rituximab to reduced intensity conditioning boosts PFS.
  19. Epperla (2017). Routine imaging does not significantly improve OS in relapsed DLBCL.